

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression

### This is the author's manuscript

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1644247> since 2019-05-07T11:48:05Z

*Published version:*

DOI:10.1183/13993003.02006-2016

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



**Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression**

Journal:	<i>European Respiratory Journal</i>
Manuscript ID	ERJ-02006-2016.R2
Manuscript Type:	Original Article
Date Submitted by the Author:	10-Jan-2017
Complete List of Authors:	<p>Di Stefano, Antonino; Istituti Clinici Scientifici Maugeri, IRCCS, Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio</p> <p>Ricciardolo, Fabio; University of Torino, Dipartimento di Scienze Cliniche e Biologiche, A.O.U., San Luigi</p> <p>Caramori, Gaetano; Sezione di Medicina Interna e Cardiorespiratoria, Scienze Mediche</p> <p>Adcock, Ian; Imperial College London, Thoracic Medicine</p> <p>Chung, Kian Fan; Imperial College, National Heart &amp; Lung Institute</p> <p>Barnes, Peter; National Heart and Lung Institute</p> <p>Brun, Paola; Università di Padova, Dipartimento di Medicina Molecolare</p> <p>Leonardi, Andrea; University of Padua, Department of Neuroscience, Ophthalmology Unit</p> <p>Ando, filippo; Università degli Studi di Messina, UOC di Malattie Respiratorie, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali</p> <p>Vallese, Davide; Istituti Clinici Scientifici Maugeri, IRCCS, Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio</p> <p>Gnemmi, Isabella; Istituti Clinici Scientifici Maugeri, IRCCS, Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio</p> <p>Righi, Luisella; Università di Torino, Dipartimento di Oncologia, SCU, Anatomia Patologica, A.O.U., San Luigi</p> <p>Cappello, Francesco; Università di Palermo, Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche</p> <p>Balbi, Bruno; Istituti Clinici Scientifici Maugeri, IRCCS, Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio</p>
Key Words:	chronic obstructive pulmonary disease, immunology/immunopathology, bacterial colonization, innate immune response

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

SCHOLARONE™  
Manuscripts

1

## Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression

Antonino Di Stefano, PhD<sup>1</sup>, Fabio LM Ricciardolo, MD, PhD<sup>2</sup>, Gaetano Caramori MD, PhD<sup>3</sup>, Ian M Adcock, PhD<sup>4</sup>, Kian Fan Chung MD<sup>4</sup>, Peter J Barnes MD<sup>4</sup>, Paola Brun, PhD<sup>5</sup>, Andrea Leonardi, MD<sup>6</sup>, Filippo Andò MD<sup>7</sup>, Davide Vallese, PhD<sup>1</sup>, Isabella Gnemmi<sup>1</sup>, Luisella Righi, MD<sup>8</sup>, Francesco Cappello, MD<sup>9,10</sup>, Bruno Balbi, MD<sup>1</sup>

<sup>1</sup>Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Istituti Clinici Scientifici Maugeri SpA, Società Benefit, Veruno (NO), Italy,

<sup>2</sup>Dipartimento di Scienze Cliniche e Biologiche, A.O.U., Divisione di Pneumologia, Ospedale San Luigi, Orbassano, Università di Torino, Italy, <sup>3</sup>Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly named Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, <sup>4</sup>Airways Disease Section, National Heart and Lung Institute, Imperial College London, UK, <sup>5</sup>Dipartimento di Medicina Molecolare, Università di Padova, Italy, <sup>6</sup>Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy; <sup>7</sup>UOC di Malattie Respiratorie, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali, Università di Messina, Italy, <sup>8</sup>Dipartimento di Oncologia, SCDU, Anatomia Patologica, A.O.U., San Luigi, Orbassano, Università di Torino, Ospedale San Luigi, Orbassano, Torino, Italy <sup>9</sup>Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Sezione di Anatomia Umana, Università di Palermo, Italy, <sup>10</sup>Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.

Formatted: Not Superscript/ Subscript

**Short title:** Inflammation, bacterial load and active anti-bacterial immune response involving TLR4 and NOD1 in stable COPD ~~TLR4 expression in stable COPD~~

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

**Conflict of interest:** No conflict of interest for all the authors included in the present study


**Manuscript word count:** 30402935

1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2



**Correspondence to:**

Dr Antonino Di Stefano, PhD,  
~~Istituti Clinici Scientifici~~Fondazione Salvatore Maugeri, IRCCS,  
Divisione di Pneumologia e Laboratorio di Citoimmunopatologia  
dell'Apparato Cardio Respiratorio  
Via per Revislate, 13  
28010 Veruno (NO), Italy  
tel: +39 0322 884711  
fax: +39 0322 884776  
E-mail: [antonino.distefano@icsmaugeri.it](mailto:antonino.distefano@icsmaugeri.it)

2

**Abstract**

**Background:** Toll-like receptors (TLRs) and nod-like receptors (NLRs) are two major forms of innate immune sensors but their role in the immunopathology of stable COPD is incompletely studied.

**Objectives:** To investigate TLRs and NLRs signaling pathways in the bronchial mucosa in stable COPD

**Methods:** Using immunohistochemistry the expression of TLR2, -4, -9, NOD1, NOD2, CD14, MYD88, TIRAP, pIRAK1, IRAK4 were measured in the bronchial mucosa of subjects with stable COPD of different severity (n=34), control smokers (n=12) and non-smokers (n=12). The bronchial bacterial load of *P. aeruginosa*, *H. influenzae*, *M. catarrhalis*, *S. pneumoniae* was measured by qRT-PCR.

**Results:** TLR4 and NOD1 expression were increased in the bronchial mucosa of patients with severe/very severe stable COPD compared to control subjects. TLR4 bronchial epithelial expression correlated positively with CD4+ and CD8+ cells and the airflow obstruction. NOD1 expression correlated with CD8+ cells. The bronchial load of *P. aeruginosa* was directly correlated, but *H. influenzae* inversely correlated with the degree of airflow obstruction. Bacterial load did not correlate with inflammatory cells.

**Conclusions:** Bronchial epithelial overexpression of TLR4 and NOD1 in severe/very severe stable COPD, associated with increased bronchial inflammation and *P. aeruginosa* bacterial load, may play a role in the pathogenesis of COPD.

**Words count: 200**

**Key words**

COPD pathology, bacterial load, innate immune response, toll-like receptors and nod-like receptors

**Abbreviations:**

FEV<sub>1</sub>=forced expiratory volume in one second,

FVC= forced vital capacity.

iE-DAP= $\gamma$ -D-glutamyl-meso-diaminopimelic acid,

IRAK=IL-1 receptor-associated kinase,

LPS=lipopolysaccharide,

MYD88=myeloid differentiation primary response gene 88,

NOD=nucleotide-binding oligomerization domain,

PAMP=pathogen-associated molecular patterns,

PGN=peptidoglycan,

PRR=pattern-recognition receptors,

TIRAP=TIR domain-containing adaptor protein,

TLR=toll-like receptor,

## Introduction

~~Inflammation plays a key role in the pathogenesis of chronic obstructive pulmonary disease (COPD) (1). A symbiotic relationship between the microbiota and the innate and adaptive immune host response has been postulated (-2, 3). Immune host responses to microbiota challenges are balanced in such a way as to maintain the microbiota diversity required for induction of protective responses to pathogens -(2, 3). Chronic obstructive pulmonary disease (COPD) is characterized by an abnormal immune response in the lower airways (1).~~ The innate immune system recognizes microbial pathogens through

pattern-recognition receptors (PRRs), which detect the pathogen-associated molecular patterns (PAMPs) and induce inflammatory host responses and activation of the adaptive immune responses (2,3).

Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are two major ~~PRRs~~forms of innate immune sensors, which provide responses against pathogenic invasion or tissue injury (4). TLR2 recognizes lipoteichoic acid from Gram positive bacteria and some non-typical lipopolysaccharides (LPS) of Gram negative bacteria (5); TLR4 recognizes LPS and some endogenous ligands (5) and TLR9 is involved in viral A/D- and bacterial B/K-type CpG DNA recognition (6). CD14 acts as a co-receptor (along with TLR4) for the detection of (LPS) but can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). Although LPS is considered its main ligand, CD14 also recognizes other ~~PAMP~~pathogen-associated molecular patterns such as lipoteichoic acid (7).

~~Nucleotide-binding oligomerization domain~~ (NOD)1 and NOD2 recognize intracellular bacteria through identification of peptidoglycan (PGN) components, such as a muramyl dipeptide (MDP) found in almost all bacteria, or via  $\gamma$ -D-glutamyl-meso-diaminopimelic acid (iE-DAP) found in ~~the~~ Gram-negative bacteria (8). Both myeloid differentiation primary response gene 88 (MYD88)-dependent and -independent (involving the CD14) signaling

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial

Formatted: Font: (Default) Arial



pathways are activated downstream of TLR activation (9,10). Upon receptor stimulation, MYD88 recruits interleukin-1 receptor-associated kinase (IRAK)-4 to TLRs and induces IRAK-1 phosphorylation, followed, in turn, by AP-1 activation and nuclear translocation and/or I $\kappa$ B degradation and NF- $\kappa$ B nuclear activation (11-14). TIR domain-containing adaptor protein (TIRAP) is essential for the MYD88-dependent signaling pathway through TLR2 and TLR4 activation (15).

Abnormalities in any of these innate sensor-mediated processes may result in excessive inflammation due to either hyperactive innate immune signaling or sustained compensatory adaptive immune activation (4,5). These characteristics have been observed in the lower airways of patients with stable COPD (1). We hypothesize the detection of bacterial proteins [occursis-activated](#) to a greater extent in more severe COPD.

The aim of this study was to investigate TLRs and NLRs signaling pathways in the bronchial mucosa in relation to the bronchial bacterial load of patients with stable COPD of differing severity and control subjects.

## Methods

### *Subjects*

All COPD patients and control subjects who underwent bronchoscopy and bronchial biopsies were recruited from the Respiratory Medicine Unit of the Fondazione Salvatore Maugeri, Institute of Veruno (Veruno, Italy). In COPD patients, the severity of the airflow obstruction was graded using current GOLD criteria [http://goldcopd.org/]. All former smokers had stopped smoking for at least one year. COPD and chronic bronchitis were defined, according to international guidelines, [http://goldcopd.org/]. All COPD patients were stable with no exacerbation in the six months prior to bronchoscopy. None of the subjects was treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids in the month prior bronchoscopy. The study conformed to the Declaration of Helsinki and was approved by the ethics committees of the Fondazione Salvatore Maugeri [Veruno (Novara), Italy], the University Hospital of Ferrara, Italy. Written informed consent was obtained from each subject and bronchial biopsies were performed according to the local ethic committee guidelines.

A detailed description of subjects, lung function tests, fibreoptic bronchoscopy and processing of bronchial biopsies, immunohistochemistry, scoring system for immunohistochemistry, double staining, quantification of bacterial load and "*in vitro*" experiments performed on normal human bronchial epithelial (NHBE) cells and details of statistical analysis are provided in the supplementary material.

Formatted: Font: Italic

### **Statistical analysis**

The numbers of patients used in each group was based on previous studies which examined differences in inflammatory cell numbers in bronchial biopsies (16). Differences between groups were analyzed using analysis of variance (ANOVA) for functional data. The ANOVA test was followed by the unpaired t-test for comparison between groups. The

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

8

~~Kruskal-Wallis test applied for morphologic data was followed by the Mann-Whitney U test for comparison between groups. Correlation coefficients were calculated using the Spearman rank method. Probability values of  $p < 0.05$  were considered significant. Differences between groups were analysed using analysis of variance and Kruskal-Wallis tests. Correlation coefficients were calculated using the Spearman rank method.~~

Formatted: Justified

8

## Results

### *Clinical characteristics of the subjects*

We obtained and studied bronchial biopsies from 58 subjects: 34 with stable COPD, 12 control smokers with normal lung function, and 12 non-smokers with normal lung function (**Table 1**). COPD patients were divided into two groups: mild/moderate (GOLD stage I-II, n=16) and severe/very severe GOLD stage III-IV, n=18) [www.goldcopd.org]. There was no difference in age between the subjects in ~~the all~~ four groups. The smoking history was similar in the three smoking groups. Values of FEV<sub>1</sub> (% predicted) and FEV<sub>1</sub>/FVC (%) differed significantly between total COPD patients (mild/moderate and severe/very severe) and both control groups (healthy smokers and healthy non-smokers). Lung function in severe/very severe COPD patients also differed significantly from mild/moderate COPD patients (ANOVA: p<0.0001 for FEV<sub>1</sub>% predicted and FEV<sub>1</sub>/FVC% values). Thirty-five percent (n=12) of the total COPD patients and 25% (n=3) of healthy smokers with normal lung function also had symptoms of chronic bronchitis but this was not significant~~ly~~.

### *Inflammatory cells in the bronchial biopsies*

The results of the immunohistochemical ~~analysisstudy~~ are summarised in **Table 2**. These data, obtained from stable COPD patients ~~by immunohistochemistry~~, confirm previously reported results showing higher numbers of neutrophils in severe/very severe COPD (**Table 2**) (16). There was also a trend towards increased CD8+ cell numbers in severe and very severe patients but this did not reach significance according to the Kruskal-Wallis test. COPD patients with chronic bronchitis had a similar number of neutrophils when compared with COPD patients without chronic bronchitis (16, 17).

~~-Immunohistochemistry for the TLRs and NLRs signaling pathways in the bronchial biopsies~~

Formatted: No widow/orphan control

The results of the immunohistochemical study for the TLRs and NLRs signaling pathways are summarized in **Table 2**.

#### *Immunohistochemistry for the TLRs and NLRs signaling pathways in the bronchial epithelium*

The expression of TLR4 in the bronchial epithelium was increased in severe/very severe stable COPD compared to non-smoking control subjects ( $p=0.0027$ ) (**Table 2, Figure E1**).

There was a trend towards significance between these COPD patients and control smokers with normal lung function ( $p=0.054$ ). The expression of TLR4 in the bronchial epithelium was also increased in mild/moderate stable COPD patients compared with non-smoking control subjects ( $p=0.024$ ). Similarly, the expression of NOD1 in the bronchial epithelium was increased in severe/very severe stable COPD compared to mild/moderate stable COPD patients ( $p=0.036$ ) and non-smoking control subjects ( $p=0.006$ ) (**Table 2, Figure E2**). NOD1 expression also trended towards significance between severe/very severe stable COPD patients and control smokers with normal lung function ( $p=0.054$ ).

The bronchial epithelium expression of both MYD88 (Kruskal-Wallis: $p=0.059$ , Mann-Whitney: $p=0.012$  and  $p=0.038$ , respectively) and TIRAP (Kruskal-Wallis: $p=0.082$ , Mann-Whitney: $p=0.035$  and  $p=0.047$ , respectively) –also tended to be increased in severe/very severe stable COPD patients compared to mild/moderate COPD and control smokers with normal lung function (**Table 2**). No significant differences were observed for the other molecules studied (**Table 2**). These data are also summarized in **Figure 1A**.

#### *Immunohistochemistry for the TLRs and NLRs signaling pathways in the bronchial lamina propria*

TLR4 was increased in severe/very severe COPD ( $p=0.027$ ) and mild/moderate COPD ( $p=0.015$ ) compared to control smokers (**Table 2, Figure E1**). NOD1 was increased in

severe/very severe COPD compared to control smokers ( $p=0.022$ ) and control non-smokers ( $p=0.002$ ). It was also increased in mild/moderate COPD ( $p=0.023$ ) compared to control non-smokers (**Table 2, Figure E2**). IRAK4 tended to be increased in mild/moderate COPD (Kruskal-Wallis:  $p=0.071$ , Mann Whitney:  $p=0.017$ ) compared to control smokers (**Table 2**). No statistical differences were observed for the other molecules studied (**Table 2**). These data are summarized in **Figure 1B**. Double staining for identification of CD8+ (T-cell), CD68+ (macrophage) and CD31+ (endothelial) cells co-expressing TLR4 and NOD1 was performed in three representative COPD patients. The percentage of (mean $\pm$ s.e.) CD8+ TLR4+, CD68+TLR4+ and CD31+TLR4+ double stained cells were 51 $\pm$ 11%, 54 $\pm$ 12% and 61 $\pm$ 5%, respectively; the percentage of CD8+ NOD1+, CD68+NOD1+ and CD31+NOD1+ double stained cells were 31 $\pm$ 10%, 30 $\pm$ 5% and 43 $\pm$ 5%, respectively (**Figure E3**).

#### *Quantification of bacterial load in the bronchial biopsies*

The results of the quantification of the bacterial load in bronchial biopsies are summarized in **Table 3** and **Figure 1C**. When data were expressed as absolute numbers, *H. influenzae* was decreased in severe/very severe COPD compared to mild/moderate COPD ( $p=0.011$ ) and control smokers ( $p=0.0013$ ). No significant differences were observed for *P. aeruginosa*, *M. catarrhalis* and *S. pneumoniae* (**Table 3**). To evaluate changes on the relative proportions of each bacterium studied, we expressed these data as percentage of the total load value constituted by the sum of the four bacteria studied. The percentage of *P. aeruginosa* tended to be increased in severe/very severe stable COPD compared to control smokers with normal lung function (Kruskal Wallis:  $p=0.050$ , Mann-Whitney:  $p=0.012$ ); the percentage of *H. influenzae* was significantly decreased in severe/very severe COPD compared to mild/moderate COPD ( $p=0.029$ ) and control smokers ( $p=0.010$ ) (**Table 3, Figure 1C**).

1  
2  
3  
4  
5  
6  
7  
8  
9 *Quantification of TLR4 mRNA in "in vitro" H<sub>2</sub>O<sub>2</sub> treated bronchial epithelial cells.*

10 Bronchial epithelial (16HBE) cells treated with H<sub>2</sub>O<sub>2</sub> (100μM) showed significantly  
11 increased TLR4 mRNA levels after 2h (**Figure 1D**).  
12  
13  
14

15  
16 *Correlations between clinical parameters, number of inflammatory cells, TLRs and NLRs*  
17 *signaling pathways expression and bacterial load in the bronchial biopsies*  
18


19  
20 In all smokers, the degree of TLR4 immunostaining in the bronchial epithelium was  
21 positively correlated with the numbers of CD8+ cells (r=0.630, p=0.018) and CD4+ cells  
22 (r=0.580, p=0.029) in the bronchial lamina propria. In addition, in all smokers, the degree  
23 of TLR4 immunostaining in bronchial epithelium was inversely correlated with the FEV<sub>1</sub>%  
24 of the predicted (r=-0.36, p=0.019) and the FEV<sub>1</sub>/FVC% (r=-0.39, p=0.009). When the  
25 analysis was restricted to patients with stable COPD alone, the correlations between the  
26 degree of TLR4 immunostaining in the bronchial epithelium with FEV<sub>1</sub>% predicted (r=-  
27 0.37, p=0.037) and FEV<sub>1</sub>/FVC ratio (r=-0.50, p=0.005) was maintained (**Figure 2**). In all  
28 smokers, NOD1 immunostaining in the lamina propria was inversely correlated with the  
29 FEV<sub>1</sub>% predicted values (r=-0.39, p=0.019) and positively correlated with the numbers of  
30 CD8+ cells (r= 0.538, p=0.044).  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Interestingly, in all smokers, the bronchial load of *P. aeruginosa* was inversely correlated  
41 with the FEV<sub>1</sub>% of the predicted values (r=-0.41, p=0.012) (**Figure 3**); whereas the reverse  
42 effect was seen with the bronchial load of *H. influenzae* which was positively correlated  
43 with the FEV<sub>1</sub>% of the predicted (r=0.458, p=0.005) (**Figure 3**). This association was also  
44 maintained in the COPD patient group [when studied separately](#) (r=0.424, p=0.025).  
45  
46  
47  
48  
49

50 No other statistically significant correlations were found between clinical parameters,  
51 expression of bacterial receptors, number of inflammatory cells and bacterial load.  
52  
53  
54

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

13



13



## Discussion

We have shown here that TLR4 and NOD1 protein expression is enhanced in the bronchial mucosa of patients with severe/very severe COPD compared to control subjects. In addition the bronchial epithelial expression of TLR4 correlates positively with the numbers of CD4+ and CD8+ cells in the bronchial mucosa and with the degree of airflow obstruction. NOD1 expression also correlated with CD8+ cell numbers. The degree of airflow obstruction was positively correlated with an increased load of *P. aeruginosa* and a decreased load of *H. influenzae* in the bronchial biopsies in all smokers and in patients with stable COPD.

A previous study ~~has~~ found no significant differences in [TLR4 expression in](#) the bronchial mucosa ~~expression of TLR4~~ of mild/moderate stable COPD patients compared to control subjects, while the percentage of CD8+ cells co-expressing TLR4 was increased (18). The difference ~~between with~~ the results reported here could be due to the low number of COPD ~~patients~~ (n=8) and control subjects (n=5) studied (18) and [also due](#) to the different severity of ~~their the~~ COPD patients. In all smokers and patients with COPD, we found a significant positive correlation between TLR4 epithelial expression and numbers of CD8+ and CD4+ cells in the lamina propria, showing an association between bronchial inflammation and upregulation of TLR4 in stable COPD. Furthermore, in agreement with our present data, increased TLR4 expression was reported by Western blotting in GOLD stage 4 COPD patients compared to control non-smokers (19). In contrast, Lee and colleagues reported decreased TLR4 levels associated with increased bronchial obstruction and increased emphysema score on lung lysates of smokers (20) confirming the need for further investigations to correctly position our present data. We here showed that CD8+, CD68+ and CD31+ cells mainly contributed to the up-regulation of TLR4 and NOD1 in bronchial biopsies of COPD patients. In agreement, using flow

cytometric analysis, CD8+ cells co-expressing TLR4 were also increased in the peripheral lung tissue of COPD patients compared to control smokers (21).

TLR4 recognises lipopolysaccharides (LPS), the major surface component of Gram-negative bacteria (5). Lipid A is the pro-inflammatory component of LPS and TLR4 is required for the recognition of lipid A of *P. aeruginosa* (22) suggesting that its overexpression in the bronchial epithelium of severe/very severe stable COPD patients may be important for sensing and responding to persistent colonization of the lower airways of these patients (23). Interestingly, *in vitro*, TLR4 activates NF- $\kappa$ B and propagate and maintain oxidative/nitrosative cellular stress that are both involved in the pathogenesis of stable COPD (1,24).

Oxidative stress is more pronounced in advanced COPD (1) and *in vitro* both tobacco smoking exposure (18) and oxidative stress (25) may upregulate TLR4 expression. In our *in vitro* experiments, using human bronchial epithelial cells (16HBE) treated with H<sub>2</sub>O<sub>2</sub>, we showed that oxidative stress induced TLR4 mRNA. Recent evidence in smoking mice (26) indicates that cigarette smoke significantly enhanced *tlr4* mRNA expression after 4 (1.77 fold) and 12 weeks (1.53 fold). Furthermore, ozone enhanced *tlr4* mRNA in the lungs of mice after 6 weeks of exposure is completely ablated by treatment with N-acetylcysteine (unpublished data). This data, taken together, [may](#) indicates that increased oxidative stress ~~in COPD patients~~ [could be](#) capable of up-regulating TLR4 [also](#) in the bronchi of stable COPD patients, [alven though specific studies in humans need to be performed to confirm this hypothesis.](#)

We also demonstrated [here for the first time](#), ~~an~~ increased expression of NOD1 in bronchial epithelium and lamina propria of stable COPD patients compared to control subjects, suggesting an involvement of this cytosolic protein in the recognition process of bacterial cell wall components in the bronchial mucosa of patients with stable COPD (27). *In vitro* human bronchial epithelial cells challenged with *M. catarrhalis* show an increased

1  
2  
3  
4  
5  
6  
7 CXCL-8 expression that is blocked by NOD1 inhibitors (28). In addition, *in vitro* NOD1  
8 agonists activates NF- $\kappa$ B in human endothelial cells (29), supporting the role of NOD1 in  
9 sustaining bronchial inflammation.  
10

11  
12 The increased expression of MYD88 in the bronchial epithelium of patients with  
13 severe/very severe stable COPD compared to control smokers with normal lung function,  
14 without significant differences in CD14 expression, suggests the involvement of a MYD88-  
15 dependent downstream signaling pathway in the immunopathology of the bronchial  
16 mucosa of stable COPD patients. This is in keeping with our data showing ~~a tendentially~~  
17 increased expression of TIRAP in the bronchial epithelium of our severe/very severe  
18 COPD patients, an index of MYD88-dependent pathway activation (15) (**Figures 1 and 4**).  
19  
20

21  
22 The decreased *H. influenzae* load observed in the bronchial mucosa of our patients  
23 with severe/very severe stable COPD compared to mild/moderate COPD and control  
24 smokers with normal lung function is in keeping with previous studies showing a  
25 fundamental role of TLR4 activation in the clearance of this bacteria from the mouse lung  
26 (30,31). This is also in agreement with previous studies showing that *H. influenzae* is  
27 virtually absent in severe/very severe COPD lung tissues and increased in milder forms of  
28 COPD (32). The absence of *H. influenzae* may also provide a niche for colonization by  
29 other pathogenic bacteria such as new strains of *P. aeruginosa* (32,33).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

Formatted: Font: Italic

41  
42 Our data on the bronchial bacterial load are ~~only apparently~~ discordant with a  
43 previous study performed in ~~the lung parenchymal~~ tissues. ~~This showed~~ no significant  
44 differences in total bacterial load between advanced stable COPD and control subjects  
45 (34) ~~and may reflect. This may be due to~~ the different ~~lower airway~~ compartments ~~of the~~  
46 ~~lower airways~~ examined. ~~In fact,~~ ~~P~~previous studies have clearly demonstrated a  
47 progressive decrease of the total bacterial load from upper to lower airways and lung  
48 parenchyma (32,33,35), and this makes more difficult to identify significant differences  
49 between patients with stable COPD of different severities and control subjects in the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 presence of very low levels of total bacterial load. This difference may also influence the  
8 related immune host response developing in the bronchi and lung tissue (different  
9 compartments) of COPD patients when compared to control subjects. These  
10 considerations are also reinforced by the data of Cabrera-Rubio et al. (36) showing that in  
11 patients with stable COPD the microbiota composition obtained by the analysis of  
12 bronchial biopsies and bronchoalveolar lavage better represents the lower airway bacterial  
13 composition compared to the analysis of sputum and bronchial aspirate samples (36).  
14  
15  
16  
17  
18  
19

20 Neither *P. aeruginosa* nor *H. influenzae*, expressed as absolute number or as  
21 percentage, were correlated with inflammatory cells (CD8+, CD68+ neutrophils) or  
22 bacterial-related molecules (TLR4, NOD1) mainly expressed in the bronchial biopsies.  
23  
24 This finding suggests that in stable disease the microbiota may not be directly related to  
25 the classical COPD inflammatory response developing in the bronchial mucosa. This  
26 seems to be in contrast to the situation during COPD exacerbations where a concomitant  
27 increase of bronchial inflammation (37), microbiota load (38) and TLR4 expression (39)  
28 has been observed. However, a comprehensive study of pathogen-related bacteria and  
29 related inflammatory response in bronchial biopsies of exacerbated COPD patients is  
30 lacking. Furthermore, changes in microbial composition in the lung and gut have been  
31 linked to organ-related alterations of the immune responses. However, no studies have  
32 investigated changes in the gut microbiota of patients with COPD of increasing severity  
33 (40).  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 It is interesting to note that certain single nucleotide polymorphisms (SNPs) of the  
46 NOD2 gene were associated with more severe disease in Japanese COPD patients (41)  
47 and this area deserves more research in the future. ~~Furthermore, in our current present~~  
48 study, the expression of both IRAK4 and pIRAK1, which favorfavoring NF- $\kappa$ B nuclear  
49 activation (11), were both over well expressed in the bronchial epithelium and lamina  
50 propria of all subjects studied. This indicates, suggesting that the bronchial mucosa is  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 ~~activated an active state of the bronchial mucosa, even in COPD the absence of significant~~  
8 ~~quantitative differences between COPD patients and control groups (Figures 1 and 4).~~ A  
9 more expansive study using next generation sequencing may determine [the precise](#)  
10 differences in inflammation and immunity in these patients.  
11  
12

13  
14 As a limitation of this study, and in agreement with other authors (33), we cannot  
15 exclude a bias in the quantification of the bacterial load due to repeated antibiotic  
16 treatments, particularly in severe/very severe COPD patients, even though a one-month  
17 wash-out period from antibiotic treatments was applied in our protocol study. [In addition,](#)  
18 [the study was not powered to detect the effect of smoking cessation on these parameters](#)  
19 [and further larger studies are required to confirm these data as well as the subgroup](#)  
20 [analysis performed here.](#)  
21  
22  
23  
24  
25  
26  
27

28 In conclusion, the overexpression of TLR4 and NOD1 in the bronchial epithelium of  
29 patients with severe/very severe stable COPD, associated to increased bronchial  
30 inflammation and *P. aeruginosa* bacterial load may play a role in the pathogenesis of the  
31 disease.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

**Acknowledgements**

This work was supported by Istituti Clinici Scientifici Maugeri, SpA Società Benefit, Ricerca Corrente. IMA and PJB are supported by Wellcome Trust grant 093080/Z/10/Z. IMA, KFC and PJB are supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. The views expressed in this publication are those of the authors(s) and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health.

Author contributions: ADS, FLMR, GC, DV, FC contributed to the study design, interpretation of the data and in writing the manuscript; AC, IAB, PJB, KFC, FA, PB, AL, LR, BB contributed to a critical revision of the manuscript; IG, VS, DV, ADS contributed to the production of the data and accuracy of the data analysis.

**References**

1. **Barnes PJ.** Cellular and molecular mechanisms of chronic obstructive pulmonary disease. *Clin Chest Med.* 2014;35:71-86.
2. **Belkaid Y, Hand TW.** Role of the microbiota in immunity and inflammation. *Cell.* 2014;157:121-141.
3. **Iwasaki A, Medzhitov R.** Control of adaptive immunity by the innate immune system. *Nat Immunol.* 2015;16:343-353.
4. **Fukata M, Vamadevan AS, Abreu MT.** Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. *Semin Immunol.* 2009;21:242-53.
5. **Takeda K, Akira S.** Toll-like receptors in innate immunity. *Int Immunol.* 2005;17:1-14.
6. **Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A.** Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. *J Exp Med.* 2003;198:513-520.
7. **Ranoa DR, Kelley SL, Tapping RI.** Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. *J Biol Chem.* 2013;288:9729-41.
8. **Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ.** Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *J Biol Chem.* 2003;278:8869-8872.
9. **Hemmi H, Kaisho T, Takeda K, Akira S.** The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. *J Immunol.* 2003;170:3059-3064.
10. **Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S.** Interferon-alpha and interleukin-12 are induced differentially by Toll-

1  
2  
3  
4  
5  
6  
7 like receptor 7 ligands in human blood dendritic cell subsets. *J Exp Med*. 2002;195:1507-  
8 1512.

9  
10  
11 11. **Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S.** Cellular responses  
12 to bacterial cell wall components are mediated through MyD88-dependent signaling  
13 cascades. *Int Immunol*. 2000;12:113-117.

14  
15  
16 12. **Kawai T, Adachi O, Ogawa T, Takeda K, Akira S.** Unresponsiveness of MyD88-  
17 deficient mice to endotoxin. *Immunity*. 1999;11:115-122.

18  
19  
20 13. **Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R.** Recognition of CpG DNA is  
21 mediated by signaling pathways dependent on the adaptor protein MyD88. *Curr Biol*.  
22 2000;10:1139-1142.

23  
24  
25 14. **Häcker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H.** Immune cell  
26 activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor  
27 necrosis factor receptor-associated factor (TRAF)6. *J Exp Med*. 2000;192:595-600.

28  
29  
30 15. **Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K,**  
31 **Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S.** Essential role for TIRAP in  
32 activation of the signalling cascade shared by TLR2 and TLR4. *Nature*. 2002;420:324-329.

33  
34  
35 16. **Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A, Cappello F,**  
36 **Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, Chung KF, Barnes PJ,**  
37 **Papi A, Adcock I, Balbi B.** Innate immunity but not NLRP3 inflammasome activation  
38 correlates with severity of stable COPD. *Thorax*. 2014;69:516-524.

39  
40  
41 17. **Vallese D, Ricciardolo FL, Gnemmi I, Casolari P, Brun P, Sorbello V, Capelli A,**  
42 **Cappello F, Cavallesco GN, Papi A, Chung KF, Balbi B, Adcock IM, Caramori G, Di**  
43 **Stefano A.** Phospho-p38 MAPK expression in COPD patients and asthmatics and in  
44 challenged bronchial epithelium. *Respiration*. 2015;89:329-342.

45  
46  
47 18. **Nadigel J, Préfontaine D, Baglole CJ, Maltais F, Bourbeau J, Eidelman DH, Hamid**  
48 **Q.** Cigarette smoke increases TLR4 and TLR9 expression and induces cytokine  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7 production from CD8(+) T cells in chronic obstructive pulmonary disease. *Respir Res.*  
8 2011;12:149. doi: 10.1186/1465-9921-12-149.

9  
10  
11 19. **An CH, Wang XM, Lam HC, Ifedigbo E, Washko GR, Ryter SW, Choi AM.** TLR4  
12 deficiency promotes autophagy during cigarette smoke-induced pulmonary emphysema.  
13 *Am J Physiol Lung Cell Mol Physiol.* 2012 Nov 1;303(9):L748-57.

14  
15  
16  
17 20. **Lee SW, Kim DR, Kim TJ, Paik JH, Chung JH, Jheon S, Huh JW, Lee JH, Lee CT.**  
18 The association of down-regulated toll-like receptor 4 expression with airflow limitation and  
19 emphysema in smokers. *Respir Res.* 2012 Nov 21;13:106.

20  
21  
22  
23 21. **Freeman CM, Martinez FJ, Han MK, Washko GR Jr, McCubbrey AL, Chensue SW,**  
24 **Arenberg DA, Meldrum CA, McCloskey L, Curtis JL.** Lung CD8+ T cells in COPD have  
25 increased expression of bacterial TLRs. *Respir Res.* 2013 Feb 1;14:13.

26  
27  
28  
29 22. **Ernst RK, Hajjar AM, Tsai JH, Moskowitz SM, Wilson CB, Miller SI.** *Pseudomonas*  
30 *aeruginosa* lipid A diversity and its recognition by Toll-like receptor 4. *J Endotoxin Res.*  
31 2003;9:395-400.

32  
33  
34  
35 23. **Gallego M, Pomares X, Espasa M, Castañer E, Solé M, Suárez D, Monsó E,**  
36 **Montón C.** *Pseudomonas aeruginosa* isolates in severe chronic obstructive pulmonary  
37 disease: characterization and risk factors. *BMC Pulm Med.* 2014;14:103. doi:  
38 10.1186/1471-2466-14-103.

39  
40  
41  
42 24. **Karki R, Igwe OJ.** Toll-like receptor 4-mediated nuclear factor kappa B activation is  
43 essential for sensing exogenous oxidants to propagate and maintain oxidative/nitrosative  
44 cellular stress. *PLoS One.* 2013;8:e73840. doi: 10.1371/journal.pone.0073840. eCollection  
45 2013.

46  
47  
48  
49 25. **Lucas K, Maes M.** Role of the Toll Like receptor (TLR) radical cycle in chronic  
50 inflammation: possible treatments targeting the TLR4 pathway. *Mol Neurobiol.*  
51 2013;48:190-204. doi: 10.1007/s12035-013-8425-7.

- 1  
2  
3  
4  
5  
6  
7 26. **Haw TJ, Starkey MR Pavlidis S, Nair PM, Liu G, Hanish I, Kim RY, Foster PS,**  
8 **Adcock IM, Horvat JC, Hansbro PM.** TLR2 and TLR4 have Opposing Roles in the  
9 Pathogenesis of Cigarette Smoke-induced COPD *Am J Respir Cell Mol Biol* 2016 (in  
10 press).  
11  
12  
13  
14 27. **Leissinger M, Kulkarni R, Zemans RL, Downey GP, Jeyaseelan S.** Investigating the  
15 role of nucleotide-binding oligomerization domain-like receptors in bacterial lung infection.  
16 *Am J Respir Crit Care Med.* 2014;189:1461-1468.  
17  
18  
19  
20 28. **Slevogt H, Seybold J, Tiwari KN, Hocke AC, Jonatat C, Dietel S, Hippenstiel S,**  
21 **Singer BB, Bachmann S, Suttorp N, Opitz B.** *Moraxella catarrhalis* is internalized in  
22 respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly  
23 NOD1-dependent inflammatory immune response. *Cell Microbiol.* 2007;9:694-707.  
24  
25  
26  
27 29. **Gatheral T, Reed DM, Moreno L, Gough PJ, Votta BJ, Sehon CA, Rickard DJ,**  
28 **Bertin J, Lim E, Nicholson AG, Mitchell JA.** A key role for the endothelium in NOD1  
29 mediated vascular inflammation: comparison to TLR4 responses. *PLoS One.*  
30 2012;7:e42386.  
31  
32  
33  
34 30. **Wang X, Moser C, Louboutin JP, Lysenko ES, Weiner DJ, Weiser JN, Wilson JM.**  
35 Toll-like receptor 4 mediates innate immune responses to *Haemophilus influenzae*  
36 infection in mouse lung. *J Immunol.* 2002;168:810-815.  
37  
38  
39  
40 31. **Wieland CW, Florquin S, Maris NA, Hoebe K, Beutler B, Takeda K, Akira S, van**  
41 **der Poll T.** The MyD88-dependent, but not the MyD88-independent, pathway of TLR4  
42 signaling is important in clearing nontypeable *haemophilus influenzae* from the mouse  
43 lung. *J Immunol.* 2005;175:6042-6049.  
44  
45  
46  
47 32. **Sze MA, Dimitriu PA, Suzuki M, McDonough JE, Campbell JD, Brothers JF, Erb-**  
48 **Downward JR, Huffnagle GB, Hayashi S, Elliott WM, Cooper J, Sin DD, Lenburg ME,**  
49  
50  
51  
52  
53  
54

**Spira A, Mohn WW, Hogg JC.** Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2015;192:438-445.

33. **Dickson RP, Erb-Downward JR, Huffnagle GB.** Homeostasis and its disruption in the lung microbiome. *Am J Physiol Lung Cell Mol Physiol.* 2015;309:L1047-1055.

34. **Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, Cooper J, Sin DD, Mohn WW, Hogg JC.** The lung tissue microbiome in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2012;185:1073-1080.

35. **Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman FD, Collman RG.** Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir Crit Care Med.* 2011;184:957-963.

36. **Cabrera-Rubio R, Garcia-Núñez M, Setó L, Antó JM, Moya A, Monsó E, Mira A.** Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease *J Clin Microbiol.* 2012;50:3562-3568.

37. **Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM.** Airway eosinophilia in chronic bronchitis during exacerbations. *Am J Respir Crit Care Med.* 1994;150:1646-52.

38. **D'Anna SE, Balbi B, Cappello F, Carone M, Di Stefano A.** Bacterial-viral load and the immune response in stable and exacerbated COPD: significance and therapeutic prospects. *Int J Chron Obstruct Pulmon Dis.* 2016;11:445-453.

39. **Pace E, Ferraro M, Giarratano A, Cipollina C, Gjomarkaj M.** TLR4 up-regulation and reduced Foxp3 expression in mechanically ventilated smokers with obstructive chronic bronchitis. *COPD.* 2013 Apr;10(2):147-55.

40. **Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P,**

**Hansbro PM.** Emerging pathogenic links between microbiota and the gut-lung axis. *Nat*

*Rev Microbiol.* 2017; 15(1):55-63. doi: 10.1038/nrmicro.2016.142. Epub 2016 Oct 3.

Formatted: Font: Italian (Italy)

Formatted: Font: Bold

Formatted: Level 1, Space Before: 12 pt, After: 6 pt, Line spacing: Double

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: 12 pt

Formatted: Font: 12 pt

25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

410. Kinose D, Ogawa E, Hirota T, Ito I, Kudo M, Haruna A, Marumo S, Hoshino Y, Muro S, Hirai T, Sakai H, Date H, Tamari M, Mishima M. A NOD2 gene polymorphism is associated with the prevalence and severity of chronic obstructive pulmonary disease in a Japanese population. *Respirology*. 2012;17:164-171.

Formatted: Font: Italian (Italy)

25

Tables

Table 1. Clinical characteristics of COPD and control subjects who provided bronchial biopsies

Groups	n	Age (years)	M/F	Pack years	Ex/current smokers	FEV <sub>1</sub> (%pred) pre-β <sub>2</sub>	FEV <sub>1</sub> (%pred) Post-β <sub>2</sub>	FEV <sub>1</sub> /FVC (%)
Control non-smokers	12	63±13	10/2	0	0	117±18	ND	86±10
Control smokers with normal lung function	12	61±7	9/3	43±26	2/10	104±13	ND	81±6
COPD stages I and II (mild/moderate)	16	71±8	14/3	50±28	6/11	63±11 <sup>#</sup>	67±13	57±9 <sup>#</sup>
COPD stages III and IV (severe/very severe)	18	66±9	11/7	54±36	13/5	35±8 <sup>#&amp;</sup>	38±9	44±10 <sup>#&amp;</sup>

Patients were classified according to GOLD (<http://goldcopd.org>) levels of severity for COPD into: mild (stage I), moderate (stage II), severe (stage III), and very severe (stage IV). Data are mean±SD. For COPD patients FEV<sub>1</sub>/FVC (%) are post-bronchodilator values. Abbreviations: M, male; F, female, FEV<sub>1</sub>: forced expiratory volume in one second; FVC, forced vital capacity; ND, not determined; COPD, chronic obstructive pulmonary disease. Statistics. (ANOVA) <sup>#</sup>p<0.0001, significantly different from control smokers with normal lung function and control never-smokers; <sup>&</sup>p<0.0001, significantly different from mild/moderate COPD: (ANOVA)

27

**Table 2. Immunohistochemical quantification of innate immune molecules and cytokines related to bacterial response in bronchial biopsies**

	Control non Smokers	Control Smokers	Mild/Moderate COPD	Severe/very Severe COPD	Kruskal Wallis p value
<b>Epithelium (score 0-3)</b>					
TLR2	1.5(0.75-2)	1.5(0.75-2.5)	1.5(0.75-2)	1.75(0.75-2.5)	0.416
TLR4	1.0(0.5-2)	1.25(0.5-2)	1.25(0.75-2.25)*	1.75(0.75-3)*	<b>0.008</b>
TLR9	0.5(0.12-0.75)	0.37(0.12-1)	0.5(0-1)	0.5(0.12-1.5)	0.851
CD14	0.62(0.5-1)	0.75(0.25-1.5)	0.75(0.5-1.75)	1.0(0.5-1.75)	0.338
NOD1	2.0(0.25-2.75)	2.5(1-3)	2.5(1-2.75)	2.5(2-3)*§	<b>0.022</b>
NOD2	0(0-0)	0(0-0)	0(0-0)	0(0-0.25)	0.784
MYD88	1.62(0.75-2.75)	1.62(0.75-2.5)	1.5(0.75-2)	2(0.75-2.5)	0.059
TIRAP	1.5(0.75-2.75)	2(1-2.5)	1.75(0.5-2.5)	2.37(1-2.75)	0.082
Phospho-IRAK1	1.5(0.75-2)	1.75(0.75-2.5)	1.5(1-2.5)	2(1-2.25)	0.688
IRAK4	2.5(1.5-3)	2.37(1-3)	2.62(1.75-3)	2.5(1.5-3)	0.326
<b>Lamina Propria (cells/mm<sup>2</sup>)</b>					
TLR2	101(56-168)	124(45-185)	90(11-390)	150(12-470)	0.341
TLR4	62(46-129)	58(32-111)	99(40-285)&	111(27-344)&	<b>0.041</b>
TLR9	4(0-52)	5(0-15)	13(0-53)	4(0-90)	0.211
CD14	118(75-213)	133(21-376)	103(48-290)	161(60-312)	0.999
NOD1	153(37-355)	202(98-323)	229(145-419)*	286(161-475)*&	<b>0.007</b>
NOD2	0(0-9)	0(0-9)	0(0-11)	0(0-41)	0.780
MYD88	129(32-216)	128(44-275)	140(56-252)	138(44-339)	0.956
TIRAP	209(73-314)	176(101-376)	193(54-548)	258(39-548)	0.438
Phospho-IRAK1	322(232-441)	324(258-366)	344(185-419)	302(186-460)	0.550
IRAK4	155(70-406)	142(27-254)	206(64-387)	172(103-274)	0.071
CD4	164(101-212)	246(37-500)	258(107-731)	252(66-470)	0.206
CD8	147(76-301)	179(86-657)	195(86-523)	244(111-355)	0.365
CD68	284(128-516)	275(97-904)	367(158-759)	340(204-1054)	0.671
Neutrophil Elastase	93(58-166)	97(45-308)	94(28-512)	151(47-470)*&	0.045

27

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Abbreviations: COPD, chronic obstructive pulmonary disease. Data expressed as median (range); n.d. not determined. Statistics: The Kruskal-Wallis test was used for multiple comparisons followed by Mann-Whitney U test for comparison between groups: \*p<0.05, significantly different from control non smokers; &p<0.05, significantly different from control smokers with normal lung function; §p<0.05, significantly different from mild/moderate COPD. The exact “p” values for comparison between groups are given in the Results section.




Table 3. Bacterial load in bronchial biopsies of COPD patients and control subjects

Bacterial load/mm <sup>2</sup>	Control non-smokers (n=5)	Control Smokers (n=9)	Mild/moderate COPD (n=13)	Severe/very severe COPD (n=15)	Kruskal Wallis (p value)
<b>16S</b>	5809±11269	4014±7126	6026±15477	810±1377	0.288
<i>Pseudomonas aeruginosa</i>	167±157 (78.8±23.3)	117±122 (67.2±22.6)	143±149 (77.2±23.9)	61±62 (88.8±20.2)	0.451 (0.050)
<i>Haemophilus influenzae</i>	42±59 (20.6±23.9)	51±74 (31.8±22.1)	28±38 (22.6±24.0)	5±8 <sup>&amp;§</sup> (10.7±20.5) <sup>&amp;§</sup>	0.007 (0.029)
<i>Moraxella catarrhalis</i>	0.8±1.1 (0.6±1.3)	1±2.2 (0.7±1.9)	0.1±0.3 (0.07±0.26)	0.2±0.7 (0.47±1.25)	0.567 (0.924)
<i>Streptococcus pneumoniae</i>	0.06±0.13 (0.0±0.0)	0.0±0.0 (0.0±0.0)	0.11±0.34 (0.07±0.26)	0.0±0.0 (0.0±0.0)	0.710 (0.986)

Abbreviations: 16S=total bacterial load. The bacterial load (copies/ml) is normalized for bronchial biopsy superficial layer (mm<sup>2</sup>). In brackets is the percentage of each bacterium studied over the total load value including *P. aeruginosa*+ *H. influenzae*+ *M. catarrhalis*+ *S. pneumoniae*. Data expressed as mean±Standard Error. Statistics: The Kruskal-Wallis test was used for multiple comparisons followed by Mann-Whitney U test for comparison between groups: \*p<0.05, significantly different from control non-smokers; &p<0.05, significantly different from control smokers with normal lung function; §p<0.05, significantly different from mild/moderate COPD. The exact "p" values for comparison between groups are given in the Results section.



### Figure Legends

**Figure 1.** Schematic representation of the molecular variations related to bacterial-related (panels a, b) molecules in the bronchial epithelium (panel a) and in the bronchial lamina propria (panel b) of control non-smokers, control smokers, mild/moderate stable COPD and severe/very severe stable COPD patients. With worsening of the disease, levels of TLR4 and NOD1 increase in bronchial epithelium (panel a) and in lamina propria (panel b). Panel (c) shows the *P. aeruginosa* and the *H. influenzae* variations in control subjects and in COPD patients of increasing severity. With worsening of the disease, levels of *P. aeruginosa* increase, while levels of *H. influenzae* decrease in bronchial biopsies. Panel (d) shows the TLR4 mRNA significant increase induced by H<sub>2</sub>O<sub>2</sub> stimulation of bronchial epithelial cells (16HBE) at 2h after the oxidative stimulus. Data in panels a, b, c, d are expressed as median±Standard Error.

\*significantly different from control non-smokers; &significantly different from control smokers; §significantly different from mild/moderate COPD. CNS=Control non-smokers; CS=Control smokers; M COPD=Mild/moderate COPD; S COPD=Severe/very severe COPD.

**Figure 2.** Regression analysis between TLR4 scored epithelial values and FEV1% predicted (panels a, c) and TLR4 scored epithelial values vs FEV1/FVC% (panels b, d). Correlations were performed in all smokers (panels a, b) and in patients with COPD alone (panels c, d). The lung functional indices of bronchial obstruction were significantly and inversely correlated to the immune expression of TLR4 in the bronchial epithelium of all smokers and of patients with COPD alone. Correlation coefficients were calculated using the Spearman rank method.

**Figure 3.** Regression analysis between FEV1% lung functional values and percentage of *P. aeruginosa* (panels a, c) and percentage of *H. influenzae* (panels b, d) in all smokers (panels a, b) and COPD patients (panels c, d). In the bronchial mucosa increased values of bronchial obstruction were associated to an increased percentage of *P. aeruginosa* in all smokers and a decreased percentage of *H. influenzae* in all smokers and patients with COPD in the bronchial mucosa. Correlation coefficients were calculated using the Spearman rank method.

**Figure 4.** *TLR4 and NOD1 signaling in COPD.* In the presence of concomitant oxidative stress stimuli, pathogen-associated molecular patterns (PAMPs) from micro-organisms and endogenous molecules termed danger-associated molecular patterns (DAMPs) stimulate TLR4 leading to the recruitment of the TLR signaling adaptors myeloid differentiation primary response protein 88 (MYD88) and the adapter molecule toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP). The MYD88 dependent pathway recruits the IL-1R-associated kinases (IRAKs) family of proteins which leads to  $\text{I}\kappa\text{B}$  phosphorylation resulting in the activation and nuclear translocation of NF- $\kappa\text{B}$  which can be responsible for the over-expression of numerous inflammatory genes. TLR4, MYD88, TIRAP and p65 (NF- $\kappa\text{B}$ ) result increased in COPD patients. Bacterial PG-derived peptides  $\gamma$ -D-glutamyl-m-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP) are recognized by the cytosolic receptors termed nucleotide-binding oligomerization domain (NOD)1 and NOD2. NOD1 and NOD2 through CARD-CARD interactions may stimulate downstream IKK complex which in turn, phosphorylates the NF- $\kappa\text{B}$  inhibitor  $\text{I}\kappa\text{B}\alpha$  followed by the NF- $\kappa\text{B}$  activation and nuclear translocation. Gram-negative bacteria preferentially activate NOD1 which was found up-regulated in our present study in COPD patients.

1  
2  
3 **Bronchial inflammation and bacterial load in stable COPD is associated with TLR4**  
4 **overexpression**  
5  
6  
7

8 Antonino Di Stefano, PhD<sup>1</sup>, Fabio LM Ricciardolo, MD, PhD<sup>2</sup>, Gaetano Caramori MD,  
9 PhD<sup>3</sup>, Ian M Adcock, PhD<sup>4</sup>, Kian Fan Chung MD<sup>4</sup>, Peter J Barnes MD<sup>4</sup>, Paola Brun, PhD<sup>5</sup>,  
10 Andrea Leonardi, MD<sup>6</sup>, Filippo Andò MD<sup>7</sup>, Davide Vallese, PhD<sup>1</sup>, Isabella Gnemmi<sup>1</sup>,  
11 Luisella Righi, MD<sup>8</sup>, Francesco Cappello, MD<sup>9,10</sup>, Bruno Balbi, MD<sup>1</sup>  
12  
13  
14  
15

16 <sup>1</sup>Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio  
17 Respiratorio, Istituti Clinici Scientifici Maugeri SpA, Società Benefit, Veruno (NO), Italy,  
18 <sup>2</sup>Dipartimento di Scienze Cliniche e Biologiche, A.O.U., San Luigi, Orbassano, Università  
19 di Torino, Italy, <sup>3</sup>Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle  
20 Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly named Centro di Ricerca su  
21 Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara,  
22 <sup>4</sup>Airways Disease Section, National Heart and Lung Institute, Imperial College London,  
23 UK, <sup>5</sup>Dipartimento di Medicina Molecolare, Università di Padova, Italy, <sup>6</sup>Department of  
24 Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy; <sup>7</sup>UOC di Malattie  
25 Respiratorie, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini  
26 Morfologiche e Funzionali, Università di Messina, Italy, <sup>8</sup>Dipartimento di Oncologia, SCU,  
27 Anatomia Patologica, A.O.U., San Luigi, Orbassano, Università di Torino, Italy  
28 <sup>9</sup>Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Sezione di Anatomia  
29 Umana, Università di Palermo, Italy, <sup>10</sup>Euro-Mediterranean Institute of Science and  
30 Technology (IEMEST), Palermo, Italy.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **Short title:** Inflammation, bacterial load and active anti-bacterial immune response  
44 involving TLR4 and NOD1 in stable COPD  
45  
46  
47

48 **Conflict of interest:** No conflict of interest for all the authors included in the present study  
49  
50

51 **Manuscript word count: 3040**  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Correspondence to:**

Dr Antonino Di Stefano, PhD,  
Istituti Clinici Scientifici Maugeri, IRCCS,  
Divisione di Pneumologia e Laboratorio di Citoimmunopatologia  
dell'Apparato Cardio Respiratorio  
Via per Revislate, 13  
28010 Veruno (NO), Italy  
tel: +39 0322 884711  
fax: +39 0322 884776  
E-mail: [antonino.distefano@icsmaugeri.it](mailto:antonino.distefano@icsmaugeri.it)

**Abstract**

**Background:** Toll-like receptors (TLRs) and nod-like receptors (NLRs) are two major forms of innate immune sensors but their role in the immunopathology of stable COPD is incompletely studied.

**Objectives:** To investigate TLRs and NLRs signaling pathways in the bronchial mucosa in stable COPD

**Methods:** Using immunohistochemistry the expression of TLR2, -4, -9, NOD1, NOD2, CD14, MYD88, TIRAP, pIRAK1, IRAK4 were measured in the bronchial mucosa of subjects with stable COPD of different severity (n=34), control smokers (n=12) and non-smokers (n=12). The bronchial bacterial load of *P. aeruginosa*, *H. influenzae*, *M. catarrhalis*, *S. pneumonie* was measured by qRT-PCR.

**Results:** TLR4 and NOD1 expression were increased in the bronchial mucosa of patients with severe/very severe stable COPD compared to control subjects. TLR4 bronchial epithelial expression correlated positively with CD4+ and CD8+ cells and the airflow obstruction. NOD1 expression correlated with CD8+ cells. The bronchial load of *P. aeruginosa* was directly correlated but *H. influenzae* inversely correlated with the degree of airflow obstruction. Bacterial load did not correlate with inflammatory cells.

**Conclusions:** Bronchial epithelial overexpression of TLR4 and NOD1 in severe/very severe stable COPD, associated with increased bronchial inflammation and *P. aeruginosa* bacterial load, may play a role in the pathogenesis of COPD.

**Word count: 200**

**Key words**

COPD pathology, bacterial load, innate immune response, toll-like receptors and nod-like receptors

**Abbreviations:**

FEV<sub>1</sub>=forced expiratory volume in one second,

FVC= forced vital capacity.

iE-DAP= $\gamma$ -D-glutamyl-meso-diaminopimelic acid,

IRAK=IL-1 receptor-associated kinase,

LPS=lipopolysaccharide,

MYD88=myeloid differentiation primary response gene 88,

NOD=nucleotide-binding oligomerization domain,

PAMP=pathogen-associated molecular patterns,

PGN=peptidoglycan,

PRR=pattern-recognition receptors,

TIRAP=TIR domain-containing adaptor protein,

TLR=toll-like receptor,

## Introduction

Inflammation plays a key role in the pathogenesis of chronic obstructive pulmonary disease (COPD) (1). A symbiotic relationship between the microbiota and the innate and adaptive immune host response has been postulated (2, 3). Immune host responses to microbiota challenges are balanced in such a way as to maintain the microbiota diversity required for induction of protective responses to pathogens (2, 3). The innate immune system recognizes microbial pathogens through pattern-recognition receptors (PRRs), which detect the pathogen-associated molecular patterns (PAMPs) and induce inflammatory host responses and activation of the adaptive immune responses (2, 3).

Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are two major PRRs, which provide responses against pathogenic invasion or tissue injury (4). TLR2 recognizes lipoteichoic acid from Gram positive bacteria and some non-typical lipopolysaccharides (LPS) of Gram negative bacteria (5); TLR4 recognizes LPS and some endogenous ligands (5) and TLR9 is involved in viral A/D- and bacterial B/K-type CpG DNA recognition (6). CD14 acts as a co-receptor (along with TLR4) for the detection of (LPS) but can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). Although LPS is considered its main ligand, CD14 also recognizes other PAMPs such as lipoteichoic acid (7).

NOD1 and NOD2 recognize intracellular bacteria through identification of peptidoglycan (PGN) components, such as a muramyl dipeptide (MDP) found in almost all bacteria, or via  $\gamma$ -D-glutamyl-meso-diaminopimelic acid (iE-DAP) found in Gram-negative bacteria (8).

Both myeloid differentiation primary response gene 88 (MYD88)-dependent and -independent (involving the CD14) signaling pathways are activated downstream of TLR activation (9, 10). Upon receptor stimulation, MYD88 recruits interleukin-1 receptor-associated kinase (IRAK)-4 to TLRs and induces IRAK-1 phosphorylation, followed, in turn, by AP-1 activation and nuclear translocation and/or I $\kappa$ B degradation and NF- $\kappa$ B

1  
2  
3 nuclear activation (11-14). TIR domain-containing adaptor protein (TIRAP) is essential for  
4  
5 the MYD88-dependent signaling pathway through TLR2 and TLR4 activation (15).  
6

7 Abnormalities in any of these innate sensor-mediated processes may result in excessive  
8  
9 inflammation due to either hyperactive innate immune signaling or sustained  
10  
11 compensatory adaptive immune activation (4, 5). These characteristics have been  
12  
13 observed in the lower airways of patients with stable COPD (1). We hypothesize the  
14  
15 detection of bacterial proteins occurs to a greater extent in more severe COPD. The aim  
16  
17 of this study was to investigate TLRs and NLRs signaling pathways in the bronchial  
18  
19 mucosa in relation to the bronchial bacterial load of patients with stable COPD of differing  
20  
21 severity and control subjects.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Methods

### *Subjects*

All COPD patients and control subjects who underwent bronchoscopy and bronchial biopsies were recruited from the Respiratory Medicine Unit of the Fondazione Salvatore Maugeri, Institute of Veruno (Veruno, Italy). In COPD patients, the severity of the airflow obstruction was graded using current GOLD criteria [<http://goldcopd.org/>]. All former smokers had stopped smoking for at least one year. COPD and chronic bronchitis were defined, according to international guidelines, [<http://goldcopd.org/>]. All COPD patients were stable with no exacerbation in the six months prior to bronchoscopy. None of the subjects was treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids in the month prior bronchoscopy. The study conformed to the Declaration of Helsinki and was approved by the ethics committees of the Fondazione Salvatore Maugeri [Veruno (Novara), Italy], the University Hospital of Ferrara, Italy. Written informed consent was obtained from each subject and bronchial biopsies were performed according to the local ethic committee guidelines.

A detailed description of subjects, lung function tests, fiberoptic bronchoscopy and processing of bronchial biopsies, immunohistochemistry, scoring system for immunohistochemistry, double staining, quantification of bacterial load and “*in vitro*” experiments performed on normal human bronchial epithelial (NHBE) cells and details of statistical analysis are provided in the supplementary material.

### **Statistical analysis**

The numbers of patients used in each group was based on previous studies which examined differences in inflammatory cell numbers in bronchial biopsies (16). Differences between groups were analyzed using analysis of variance (ANOVA) for functional data. The ANOVA test was followed by the unpaired t-test for comparison between groups. The

1  
2  
3 Kruskal-Wallis test applied for morphologic data was followed by the Mann-Whitney U test  
4  
5 for comparison between groups. Correlation coefficients were calculated using the  
6  
7 Spearman rank method. Probability values of  $p < 0.05$  were considered significant.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### *Clinical characteristics of the subjects*

We obtained and studied bronchial biopsies from 58 subjects: 34 with stable COPD, 12 control smokers with normal lung function, and 12 non-smokers with normal lung function (**Table 1**). COPD patients were divided into two groups: mild/moderate (GOLD stage I-II, n=16) and severe/very severe GOLD stage III-IV, n=18) [www.goldcopd.org]. There was no difference in age between the subjects in the four groups. The smoking history was similar in the three smoking groups. Values of FEV<sub>1</sub> (% predicted) and FEV<sub>1</sub>/FVC (%) differed significantly between total COPD patients (mild/moderate and severe/very severe) and both control groups (healthy smokers and healthy non-smokers). Lung function in severe/very severe COPD patients also differed significantly from mild/moderate COPD patients (ANOVA: p<0.0001 for FEV<sub>1</sub>% predicted and FEV<sub>1</sub>/FVC% values). Thirty-five percent (n=12) of the total COPD patients and 25% (n=3) of healthy smokers with normal lung function also had symptoms of chronic bronchitis but this was not significant.

### *Inflammatory cells in the bronchial biopsies*

The results of the immunohistochemical analysis are summarised in **Table 2**. These data, obtained from stable COPD patients, confirm previously reported results showing higher numbers of neutrophils in severe/very severe COPD (**Table 2**) (16). There was also a trend towards increased CD8+ cell numbers in severe and very severe patients but this did not reach significance according to the Kruskal-Wallis test. COPD patients with chronic bronchitis had a similar number of neutrophils when compared with COPD patients without chronic bronchitis (16, 17).

### *Immunohistochemistry*

The results of the immunohistochemical study for the TLRs and NLRs signaling pathways

1  
2  
3 are summarized in **Table 2**.

4  
5  
6  
7 *Immunohistochemistry in bronchial epithelium*

8  
9 The expression of TLR4 in the bronchial epithelium was increased in severe/very severe  
10 stable COPD compared to non-smoking control subjects ( $p=0.0027$ ) (**Table 2, Figure E1**).

11  
12 There was a trend towards significance between these COPD patients and control  
13 smokers with normal lung function ( $p=0.054$ ). The expression of TLR4 in the bronchial  
14 epithelium was also increased in mild/moderate stable COPD patients compared with non-  
15 smoking control subjects ( $p=0.024$ ). Similarly, the expression of NOD1 in the bronchial  
16 epithelium was increased in severe/very severe stable COPD compared to mild/moderate  
17 stable COPD patients ( $p=0.036$ ) and non-smoking control subjects ( $p=0.006$ ) (**Table 2,**  
18 **Figure E2**). NOD1 expression also trended towards significance between severe/very  
19 severe stable COPD patients and control smokers with normal lung function ( $p=0.054$ ).

20  
21 The bronchial epithelial expression of both MYD88 (Kruskal-Wallis: $p=0.059$ , Mann-  
22 Whitney: $p=0.012$  and  $p=0.038$ , respectively) and TIRAP (Kruskal-Wallis: $p=0.082$ , Mann-  
23 Whitney: $p=0.035$  and  $p=0.047$ , respectively) also tended to be increased in severe/very  
24 severe stable COPD patients compared to mild/moderate COPD and control smokers with  
25 normal lung function (**Table 2**). No significant differences were observed for the other  
26 molecules studied (**Table 2**). These data are also summarized in **Figure 1A**.

27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47 *Immunohistochemistry in bronchial lamina propria*

48  
49 TLR4 was increased in severe/very severe COPD ( $p=0.027$ ) and mild/moderate COPD  
50 ( $p=0.015$ ) compared to control smokers (**Table 2, Figure E1**). NOD1 was increased in  
51 severe/very severe COPD compared to control smokers ( $p=0.022$ ) and control non-  
52 smokers ( $p=0.002$ ). It was also increased in mild/moderate COPD ( $p=0.023$ ) compared to  
53 control non-smokers (**Table 2, Figure E2**). IRAK4 tended to be increased in mild/moderate  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 COPD (Kruskal-Wallis:  $p=0.071$ , Mann Whitney:  $p=0.017$ ) compared to control smokers  
4  
5 (**Table 2**). No statistical differences were observed for the other molecules studied (**Table**  
6  
7 **2**). These data are summarized in **Figure 1B**. Double staining for identification of CD8+ (T-  
8  
9 cell), CD68+ (macrophage) and CD31+ (endothelial) cells co-expressing TLR4 and NOD1  
10  
11 was performed in three representative COPD patients. The percentage of (mean $\pm$ s.e.)  
12  
13 CD8+ TLR4+, CD68+TLR4+ and CD31+TLR4+ double stained cells were 51 $\pm$ 11%,  
14  
15 54 $\pm$ 12% and 61 $\pm$ 5%, respectively; the percentage of CD8+ NOD1+, CD68+NOD1+ and  
16  
17 CD31+NOD1+ double stained cells were 31 $\pm$ 10%, 30 $\pm$ 5% and 43 $\pm$ 5%, respectively  
18  
19 (**Figure E3**).  
20  
21  
22  
23  
24

#### 25 *Quantification of bacterial load in the bronchial biopsies*

26  
27 The results of the quantification of the bacterial load in bronchial biopsies are summarized  
28  
29 in **Table 3** and **Figure 1C**. When data were expressed as absolute numbers, *H.*  
30  
31 *influenzae* was decreased in severe/very severe COPD compared to mild/moderate COPD  
32  
33 ( $p=0.011$ ) and control smokers ( $p=0.0013$ ). No significant differences were observed for *P.*  
34  
35 *aeruginosa*, *M. catarrhalis* and *S. pneumoniae* (**Table 3**). To evaluate changes on the  
36  
37 relative proportions of each bacterium studied, we expressed these data as percentage of  
38  
39 the total load value constituted by the sum of the four bacteria studied. The percentage of  
40  
41 *P. aeruginosa* tended to be increased in severe/very severe stable COPD compared to  
42  
43 control smokers with normal lung function (Kruskal Wallis:  $p=0.050$ , Mann-Whitney:  
44  
45  $p=0.012$ ); the percentage of *H. influenzae* was significantly decreased in severe/very  
46  
47 severe COPD compared to mild/moderate COPD ( $p=0.029$ ) and control smokers  
48  
49 ( $p=0.010$ ) (**Table 3, Figure 1C**).  
50  
51  
52  
53  
54

#### 55 *Quantification of TLR4 mRNA in "in vitro" H<sub>2</sub>O<sub>2</sub> treated bronchial epithelial cells.*

1  
2  
3 Bronchial epithelial (16HBE) cells treated with H<sub>2</sub>O<sub>2</sub> (100μM) showed significantly  
4  
5 increased TLR4 mRNA levels after 2h (**Figure 1D**).  
6  
7

8  
9  
10 *Correlations between clinical parameters, number of inflammatory cells, TLRs and NLRs*  
11 *signaling pathways expression and bacterial load in the bronchial biopsies*  
12

13  
14 In all smokers, the degree of TLR4 immunostaining in the bronchial epithelium was  
15  
16 positively correlated with the numbers of CD8+ cells (r=0.630, p=0.018) and CD4+ cells  
17  
18 (r=0.580, p=0.029) in the bronchial lamina propria. In addition, in all smokers, the degree  
19  
20 of TLR4 immunostaining in bronchial epithelium was inversely correlated with the FEV<sub>1</sub>%  
21  
22 of the predicted (r=-0.36, p=0.019) and the FEV<sub>1</sub>/FVC% (r=-0.39, p=0.009). When the  
23  
24 analysis was restricted to patients with stable COPD alone, the correlations between the  
25  
26 degree of TLR4 immunostaining in the bronchial epithelium with FEV<sub>1</sub>% predicted (r=-  
27  
28 0.37, p=0.037) and FEV<sub>1</sub>/FVC ratio (r=-0.50, p=0.005) was maintained (**Figure 2**). In all  
29  
30 smokers, NOD1 immunostaining in the lamina propria was inversely correlated with the  
31  
32 FEV<sub>1</sub>% predicted values (r=-0.39, p=0.019) and positively correlated with the numbers of  
33  
34 CD8+ cells (r= 0.538, p=0.044).  
35  
36

37  
38 Interestingly, in all smokers, the bronchial load of *P. aeruginosa* was inversely correlated  
39  
40 with the FEV<sub>1</sub>% of the predicted values (r=-0.41, p=0.012) (**Figure 3**); whereas the reverse  
41  
42 effect was seen with the bronchial load of *H. influenzae* which was positively correlated  
43  
44 with the FEV<sub>1</sub>% of the predicted (r=0.458, p=0.005) (**Figure 3**). This association was  
45  
46 maintained in the COPD patient group when studied separately (r=0.424, p=0.025).  
47  
48

49  
50 No other statistically significant correlations were found between clinical parameters,  
51  
52 expression of bacterial receptors, number of inflammatory cells and bacterial load.  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

We have shown here that TLR4 and NOD1 protein expression is enhanced in the bronchial mucosa of patients with severe/very severe COPD compared to control subjects. In addition the bronchial epithelial expression of TLR4 correlates positively with the numbers of CD4+ and CD8+ cells in the bronchial mucosa and with the degree of airflow obstruction. NOD1 expression also correlated with CD8+ cell numbers. The degree of airflow obstruction was positively correlated with an increased load of *P. aeruginosa* and a decreased load of *H. influenzae* in the bronchial biopsies in all smokers and in patients with stable COPD.

A previous study found no significant differences in TLR4 expression in the bronchial mucosa of mild/moderate stable COPD patients compared to control subjects, while the percentage of CD8+ cells co-expressing TLR4 was increased (18). The difference between the results reported here could be due to the low number of COPD (n=8) and control subjects (n=5) studied (18) and also due to the different severity of the COPD patients. In all smokers and patients with COPD, we found a significant positive correlation between TLR4 epithelial expression and numbers of CD8+ and CD4+ cells in the lamina propria, showing an association between bronchial inflammation and upregulation of TLR4 in stable COPD. Furthermore, in agreement with our present data, increased TLR4 expression was reported by Western blotting in GOLD stage 4 COPD patients compared to control non-smokers (19). In contrast, Lee and colleagues reported decreased TLR4 levels associated with increased bronchial obstruction and increased emphysema score on lung lysates of smokers (20) confirming the need for further investigations to correctly position our present data. We here showed that CD8+, CD68+ and CD31+ cells mainly contributed to the up-regulation of TLR4 and NOD1 in bronchial biopsies of COPD patients. In agreement, using flow cytometric analysis, CD8+ cells co-

1  
2  
3 expressing TLR4 were also increased in the peripheral lung tissue of COPD patients  
4 compared to control smokers (21).

5  
6  
7 TLR4 recognises lipopolysaccharides (LPS), the major surface component of Gram-  
8 negative bacteria (5). Lipid A is the pro-inflammatory component of LPS and TLR4 is  
9 required for the recognition of lipid A of *P. aeruginosa* (22) suggesting that its  
10 overexpression in the bronchial epithelium of severe/very severe stable COPD patients  
11 may be important for sensing and responding to persistent colonization of the lower  
12 airways of these patients (23). Interestingly, *in vitro*, TLR4 activates NF- $\kappa$ B and propagate  
13 and maintain oxidative/nitrosative cellular stress that are both involved in the pathogenesis  
14 of stable COPD (1, 24).  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 Oxidative stress is more pronounced in advanced COPD (1) and *in vitro* both  
26 tobacco smoking exposure (18) and oxidative stress (25) may upregulate TLR4  
27 expression. In our *in vitro* experiments, using human bronchial epithelial cells (16HBE)  
28 treated with H<sub>2</sub>O<sub>2</sub>, we showed that oxidative stress induced TLR4 mRNA. Recent  
29 evidence in smoking mice (26) indicates that cigarette smoke significantly enhanced *tlr4*  
30 mRNA expression after 4 (1.77 fold) and 12 weeks (1.53 fold). Furthermore, ozone  
31 enhanced *tlr4* mRNA in the lungs of mice after 6 weeks of exposure is completely ablated  
32 by treatment with N-acetylcysteine (unpublished data). This data, taken together,  
33 indicates that increased oxidative stress could be capable of up-regulating TLR4 also in  
34 the bronchi of stable COPD patients, although specific studies in humans need to be  
35 performed to confirm this hypothesis.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 We also demonstrated increased expression of NOD1 in bronchial epithelium and  
50 lamina propria of stable COPD patients compared to control subjects, suggesting an  
51 involvement of this cytosolic protein in the recognition process of bacterial cell wall  
52 components in the bronchial mucosa of patients with stable COPD (27). *In vitro* human  
53 bronchial epithelial cells challenged with *M. catarrhalis* show an increased CXCL-8  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 expression that is blocked by NOD1 inhibitors (28). In addition, *in vitro* NOD1 agonists  
4  
5 activates NF- $\kappa$ B in human endothelial cells (29), supporting the role of NOD1 in sustaining  
6  
7 bronchial inflammation.  
8

9  
10 The increased expression of MYD88 in the bronchial epithelium of patients with  
11  
12 severe/very severe stable COPD compared to control smokers with normal lung function,  
13  
14 without significant differences in CD14 expression, suggests the involvement of a MYD88-  
15  
16 dependent downstream signaling pathway in the immunopathology of the bronchial  
17  
18 mucosa of stable COPD patients. This is in keeping with our data showing increased  
19  
20 expression of TIRAP in the bronchial epithelium of our severe/very severe COPD patients,  
21  
22 an index of MYD88-dependent pathway activation (15) (**Figures 1 and 4**).  
23  
24

25 The decreased *H. influenzae* load observed in the bronchial mucosa of our patients  
26  
27 with severe/very severe stable COPD compared to mild/moderate COPD and control  
28  
29 smokers with normal lung function is in keeping with previous studies showing a  
30  
31 fundamental role of TLR4 activation in the clearance of this bacteria from the mouse lung  
32  
33 (30, 31). This is also in agreement with previous studies showing that *H. influenzae* is  
34  
35 virtually absent in severe/very severe COPD lung tissues and increased in milder forms of  
36  
37 COPD (32). The absence of *H. influenzae* may also provide a niche for colonization by  
38  
39 other pathogenic bacteria such as new strains of *P. aeruginosa* (32, 33).  
40  
41  
42

43 Our data on the bronchial bacterial load are discordant with a previous study  
44  
45 performed in lung parenchymal tissues. This showed no significant differences in total  
46  
47 bacterial load between advanced stable COPD and control subjects (34) and may reflect  
48  
49 the different lower airway compartment examined. Previous studies have clearly  
50  
51 demonstrated a progressive decrease of the total bacterial load from upper to lower  
52  
53 airways and lung parenchyma (32, 33, 35), and this makes more difficult to identify  
54  
55 significant differences between patients with stable COPD of different severities and  
56  
57 control subjects in the presence of very low levels of total bacterial load. This difference  
58  
59  
60

1  
2  
3 may also influence the related immune host response developing in the bronchi and lung  
4  
5 tissue (different compartments) of COPD patients when compared to control subjects.  
6  
7 These considerations are also reinforced by the data of Cabrera-Rubio et al. (36) showing  
8  
9 that in patients with stable COPD the microbiota composition obtained by the analysis of  
10  
11 bronchial biopsies and bronchoalveolar lavage better represents the lower airway bacterial  
12  
13 composition compared to the analysis of sputum and bronchial aspirate samples (36).  
14  
15

16  
17 Neither *P. aeruginosa* nor *H. influenzae*, expressed as absolute number or as  
18  
19 percentage, were correlated with inflammatory cells (CD8+, CD68+ neutrophils) or  
20  
21 bacterial-related molecules (TLR4, NOD1) mainly expressed in the bronchial biopsies.  
22  
23 This finding suggests that in stable disease the microbiota may not be directly related to  
24  
25 the classical COPD inflammatory response developing in the bronchial mucosa. This  
26  
27 seems to be in contrast to the situation during COPD exacerbations where a concomitant  
28  
29 increase of bronchial inflammation (37), microbiota load (38) and TLR4 expression (39)  
30  
31 has been observed. However, a comprehensive study of pathogen-related bacteria and  
32  
33 related inflammatory response in bronchial biopsies of exacerbated COPD patients is  
34  
35 lacking. Furthermore, changes in microbial composition in the lung and gut have been  
36  
37 linked to organ-related alterations of the immune responses. However, no studies have  
38  
39 investigated changes in the gut microbiota of patients with COPD of increasing severity  
40  
41 (40).  
42  
43  
44

45  
46 It is interesting to note that certain single nucleotide polymorphisms (SNPs) of the  
47  
48 NOD2 gene were associated with more severe disease in Japanese COPD patients (41)  
49  
50 and this area deserves more research in the future. Furthermore, our current study, the  
51  
52 expression of both IRAK4 and pIRAK1, which favor NF- $\kappa$ B nuclear activation (11), were  
53  
54 both over expressed in the bronchial epithelium and lamina propria of all subjects studied.  
55  
56 This indicates that the bronchial mucosa is activated in COPD (**Figures 1 and 4**). A more  
57  
58  
59  
60

1  
2  
3 expansive study using next generation sequencing may determine the precise differences  
4  
5 in inflammation and immunity in these patients.  
6

7         As a limitation of this study, and in agreement with other authors (33), we cannot  
8  
9 exclude a bias in the quantification of the bacterial load due to repeated antibiotic  
10  
11 treatments, particularly in severe/very severe COPD patients, even though a one-month  
12  
13 wash-out period from antibiotic treatments was applied in our protocol study. In addition,  
14  
15 the study was not powered to detect the effect of smoking cessation on these parameters  
16  
17 and further larger studies are required to confirm these data as well as the subgroup  
18  
19 analysis performed here.  
20  
21

22         In conclusion, the overexpression of TLR4 and NOD1 in the bronchial epithelium of  
23  
24 patients with severe/very severe stable COPD, associated to increased bronchial  
25  
26 inflammation and *P. aeruginosa* bacterial load may play a role in the pathogenesis of the  
27  
28 disease.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

This work was supported by Istituti Clinici Scientifici Maugeri, SpA Società Benefit, Ricerca Corrente. IMA and PJB are supported by Wellcome Trust grant 093080/Z/10/Z. IMA, KFC and PJB are supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. The views expressed in this publication are those of the authors(s) and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health.

Author contributions: ADS, FLMR, GC, DV, FC contributed to the study design, interpretation of the data and in writing the manuscript; AC, IAB, PJB, KFC, FA, PB, AL, LR, BB contributed to a critical revision of the manuscript; IG, VS, DV, ADS contributed to the production of the data and accuracy of the data analysis.

## References

1. **Barnes PJ.** Cellular and molecular mechanisms of chronic obstructive pulmonary disease. *Clin Chest Med.* 2014;35:71-86.
2. **Belkaid Y, Hand TW.** Role of the microbiota in immunity and inflammation. *Cell.* 2014;157:121-141.
3. **Iwasaki A, Medzhitov R.** Control of adaptive immunity by the innate immune system. *Nat Immunol.* 2015;16:343-353.
4. **Fukata M, Vamadevan AS, Abreu MT.** Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. *Semin Immunol.* 2009;21:242-53.
5. **Takeda K, Akira S.** Toll-like receptors in innate immunity. *Int Immunol.* 2005;17:1-14.
6. **Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A.** Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. *J Exp Med.* 2003;198:513-520.
7. **Ranoa DR, Kelley SL, Tapping RI.** Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. *J Biol Chem.* 2013;288:9729-41.
8. **Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ.** Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. *J Biol Chem.* 2003;278:8869-8872.
9. **Hemmi H, Kaisho T, Takeda K, Akira S.** The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. *J Immunol.* 2003;170:3059-3064.
10. **Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S.** Interferon-alpha and interleukin-12 are induced differentially by Toll-

1  
2  
3 like receptor 7 ligands in human blood dendritic cell subsets. *J Exp Med*. 2002;195:1507-  
4  
5 1512.

6  
7 11. **Takeuchi O, Takeda K, Hoshino K, Adachi O, Ogawa T, Akira S.** Cellular responses  
8  
9 to bacterial cell wall components are mediated through MyD88-dependent signaling  
10  
11 cascades. *Int Immunol*. 2000;12:113-117.

12  
13 12. **Kawai T, Adachi O, Ogawa T, Takeda K, Akira S.** Unresponsiveness of MyD88-  
14  
15 deficient mice to endotoxin. *Immunity*. 1999;11:115-122.

16  
17 13. **Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R.** Recognition of CpG DNA is  
18  
19 mediated by signaling pathways dependent on the adaptor protein MyD88. *Curr Biol*.  
20  
21 2000;10:1139-1142.

22  
23 14. **Häcker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H.** Immune cell  
24  
25 activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor  
26  
27 necrosis factor receptor-associated factor (TRAF)6. *J Exp Med*. 2000;192:595-600.

28  
29 15. **Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K,**  
30  
31 **Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S.** Essential role for TIRAP in  
32  
33 activation of the signalling cascade shared by TLR2 and TLR4. *Nature*. 2002;420:324-329.

34  
35 16. **Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A, Cappello F,**  
36  
37 **Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, Chung KF, Barnes PJ,**  
38  
39 **Papi A, Adcock I, Balbi B.** Innate immunity but not NLRP3 inflammasome activation  
40  
41 correlates with severity of stable COPD. *Thorax*. 2014;69:516-524.

42  
43 17. **Vallese D, Ricciardolo FL, Gnemmi I, Casolari P, Brun P, Sorbello V, Capelli A,**  
44  
45 **Cappello F, Cavallesco GN, Papi A, Chung KF, Balbi B, Adcock IM, Caramori G, Di**  
46  
47 **Stefano A.** Phospho-p38 MAPK expression in COPD patients and asthmatics and in  
48  
49 challenged bronchial epithelium. *Respiration*. 2015;89:329-342.

50  
51 18. **Nadigel J, Préfontaine D, Baglolle CJ, Maltais F, Bourbeau J, Eidelman DH, Hamid**  
52  
53 **Q.** Cigarette smoke increases TLR4 and TLR9 expression and induces cytokine  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 production from CD8(+) T cells in chronic obstructive pulmonary disease. *Respir Res.*  
4  
5 2011;12:149. doi: 10.1186/1465-9921-12-149.

6  
7 19. **An CH, Wang XM, Lam HC, Ifedigbo E, Washko GR, Ryter SW, Choi AM.** TLR4  
8  
9 deficiency promotes autophagy during cigarette smoke-induced pulmonary emphysema.  
10  
11 *Am J Physiol Lung Cell Mol Physiol.* 2012 Nov 1;303(9):L748-57.

12  
13 20. **Lee SW, Kim DR, Kim TJ, Paik JH, Chung JH, Jheon S, Huh JW, Lee JH, Lee CT.**  
14  
15 The association of down-regulated toll-like receptor 4 expression with airflow limitation and  
16  
17 emphysema in smokers. *Respir Res.* 2012 Nov 21;13:106.

18  
19 21. **Freeman CM, Martinez FJ, Han MK, Washko GR Jr, McCubbrey AL, Chensue SW,**  
20  
21  
22 **Arenberg DA, Meldrum CA, McCloskey L, Curtis JL.** Lung CD8+ T cells in COPD have  
23  
24 increased expression of bacterial TLRs. *Respir Res.* 2013 Feb 1;14:13.

25  
26 22. **Ernst RK, Hajjar AM, Tsai JH, Moskowitz SM, Wilson CB, Miller SI.** *Pseudomonas*  
27  
28 *aeruginosa* lipid A diversity and its recognition by Toll-like receptor 4. *J Endotoxin Res.*  
29  
30 2003;9:395-400.

31  
32 23. **Gallego M, Pomares X, Espasa M, Castañer E, Solé M, Suárez D, Monsó E,**  
33  
34  
35 **Montón C.** *Pseudomonas aeruginosa* isolates in severe chronic obstructive pulmonary  
36  
37 disease: characterization and risk factors. *BMC Pulm Med.* 2014;14:103. doi:  
38  
39 10.1186/1471-2466-14-103.

40  
41 24. **Karki R, Igwe OJ.** Toll-like receptor 4-mediated nuclear factor kappa B activation is  
42  
43 essential for sensing exogenous oxidants to propagate and maintain oxidative/nitrosative  
44  
45 cellular stress. *PLoS One.* 2013;8:e73840. doi: 10.1371/journal.pone.0073840. eCollection  
46  
47 2013.

48  
49 25. **Lucas K, Maes M.** Role of the Toll Like receptor (TLR) radical cycle in chronic  
50  
51 inflammation: possible treatments targeting the TLR4 pathway. *Mol Neurobiol.*  
52  
53 2013;48:190-204. doi: 10.1007/s12035-013-8425-7.

- 1  
2  
3 26. **Haw TJ, Starkey MR Pavlidis S, Nair PM, Liu G, Hanish I, Kim RY, Foster PS,**  
4 **Adcock IM, Horvat JC, Hansbro PM.** TLR2 and TLR4 have Opposing Roles in the  
5 Pathogenesis of Cigarette Smoke-induced COPD *Am J Respir Cell Mol Biol* 2016 (in  
6 press).  
7  
8  
9  
10  
11 27. **Leissinger M, Kulkarni R, Zemans RL, Downey GP, Jeyaseelan S.** Investigating the  
12 role of nucleotide-binding oligomerization domain-like receptors in bacterial lung infection.  
13 *Am J Respir Crit Care Med.* 2014;189:1461-1468.  
14  
15  
16  
17 28. **Slevogt H, Seybold J, Tiwari KN, Hocke AC, Jonatat C, Dietel S, Hippenstiel S,**  
18 **Singer BB, Bachmann S, Suttorp N, Opitz B.** *Moraxella catarrhalis* is internalized in  
19 respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly  
20 NOD1-dependent inflammatory immune response. *Cell Microbiol.* 2007;9:694-707.  
21  
22  
23 29. **Gatheral T, Reed DM, Moreno L, Gough PJ, Votta BJ, Sehon CA, Rickard DJ,**  
24 **Bertin J, Lim E, Nicholson AG, Mitchell JA.** A key role for the endothelium in NOD1  
25 mediated vascular inflammation: comparison to TLR4 responses. *PLoS One.*  
26 2012;7:e42386.  
27  
28  
29 30. **Wang X, Moser C, Louboutin JP, Lysenko ES, Weiner DJ, Weiser JN, Wilson JM.**  
30 Toll-like receptor 4 mediates innate immune responses to *Haemophilus influenzae*  
31 infection in mouse lung. *J Immunol.* 2002;168:810-815.  
32  
33  
34 31. **Wieland CW, Florquin S, Maris NA, Hoebe K, Beutler B, Takeda K, Akira S, van**  
35 **der Poll T.** The MyD88-dependent, but not the MyD88-independent, pathway of TLR4  
36 signaling is important in clearing nontypeable *haemophilus influenzae* from the mouse  
37 lung. *J Immunol.* 2005;175:6042-6049.  
38  
39  
40 32. **Sze MA, Dimitriu PA, Suzuki M, McDonough JE, Campbell JD, Brothers JF, Erb-**  
41 **Downward JR, Huffnagle GB, Hayashi S, Elliott WM, Cooper J, Sin DD, Lenburg ME,**  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Spira A, Mohn WW, Hogg JC.** Host Response to the Lung Microbiome in Chronic  
4 Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2015;192:438-445.

5  
6  
7 33. **Dickson RP, Erb-Downward JR, Huffnagle GB.** Homeostasis and its disruption in  
8 the lung microbiome. *Am J Physiol Lung Cell Mol Physiol.* 2015;309:L1047-1055.

9  
10 34. **Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV,**  
11 **Cooper J, Sin DD, Mohn WW, Hogg JC.** The lung tissue microbiome in chronic  
12 obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2012;185:1073-1080.

13  
14 35. **Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman**  
15 **FD, Collman RG.** Topographical continuity of bacterial populations in the healthy human  
16 respiratory tract. *Am J Respir Crit Care Med.* 2011;184:957-963.

17  
18 36. **Cabrera-Rubio R, Garcia-Núñez M, Setó L, Antó JM, Moya A, Monsó E, Mira A.**  
19 **Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary**  
20 **disease** *J Clin Microbiol.* 2012;50:3562-3568.

21  
22 37. **Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni**  
23 **P, Mapp CE, Ciaccia A, Fabbri LM.** Airway eosinophilia in chronic bronchitis during  
24 exacerbations. *Am J Respir Crit Care Med.* 1994;150:1646-52.

25  
26 38. **D'Anna SE, Balbi B, Cappello F, Carone M, Di Stefano A.** Bacterial-viral load and  
27 the immune response in stable and exacerbated COPD: significance and therapeutic  
28 prospects. *Int J Chron Obstruct Pulmon Dis.* 2016;11:445-453.

29  
30 39. **Pace E, Ferraro M, Giarratano A, Cipollina C, Gjomarkaj M.** TLR4 up-regulation and  
31 reduced Foxp3 expression in mechanically ventilated smokers with obstructive chronic  
32 bronchitis. *COPD.* 2013 Apr;10(2):147-55.

33  
34 40. **Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P,**  
35 **Hansbro PM.** Emerging pathogenic links between microbiota and the gut-lung axis. *Nat*  
36 *Rev Microbiol.* 2017; 15(1):55-63. doi: 10.1038/nrmicro.2016.142. Epub 2016 Oct 3.

1  
2  
3  
4  
5 41. Kinose D, Ogawa E, Hirota T, Ito I, Kudo M, Haruna A, Marumo S, Hoshino Y,  
6  
7 **Muro S, Hirai T, Sakai H, Date H, Tamari M, Mishima M.** A NOD2 gene polymorphism is  
8 associated with the prevalence and severity of chronic obstructive pulmonary disease in a  
9 Japanese population. *Respirology*. 2012;17:164-171.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## Tables

**Table 1. Clinical characteristics of COPD and control subjects who provided bronchial biopsies**

Groups	n	Age (years)	M/F	Pack years	Ex/current smokers	FEV <sub>1</sub> (%pred) pre-β <sub>2</sub>	FEV <sub>1</sub> (%pred) Post-β <sub>2</sub>	FEV <sub>1</sub> /FVC (%)
Control non-smokers	12	63±13	10/2	0	0	117±18	ND	86±10
Control smokers with normal lung function	12	61±7	9/3	43±26	2/10	104±13	ND	81±6
COPD stages I and II (mild/moderate)	16	71±8	14/3	50±28	6/11	63±11 <sup>#</sup>	67±13	57±9 <sup>#</sup>
COPD stages III and IV (severe/very severe)	18	66±9	11/7	54±36	13/5	35±8 <sup>#&amp;</sup>	38±9	44±10 <sup>#&amp;</sup>

Patients were classified according to GOLD (<http://goldcopd.org>) levels of severity for COPD into: mild (stage I), moderate (stage II), severe (stage III), and very severe (stage IV). Data are mean±SD. For COPD patients FEV<sub>1</sub>/FVC (%) are post-bronchodilator values. Abbreviations: M, male; F, female, FEV<sub>1</sub>: forced expiratory volume in one second; FVC, forced vital capacity; ND, not determined; COPD, chronic obstructive pulmonary disease. Statistics. (ANOVA) <sup>#</sup>p<0.0001, significantly different from control smokers with normal lung function and control never-smokers; <sup>&</sup>p<0.0001, significantly different from mild/moderate COPD: (ANOVA)

**Table 2. Immunohistochemical quantification of innate immune molecules and cytokines related to bacterial response in bronchial biopsies**

	Control non Smokers	Control Smokers	Mild/Moderate COPD	Severe/very Severe COPD	Kruskal Wallis p value
<b>Epithelium (score 0-3)</b>					
TLR2	1.5(0.75-2)	1.5(0.75-2.5)	1.5(0.75-2)	1.75(0.75-2.5)	0.416
TLR4	1.0(0.5-2)	1.25(0.5-2)	1.25(0.75-2.25)*	1.75(0.75-3)*	<b>0.008</b>
TLR9	0.5(0.12-0.75)	0.37(0.12-1)	0.5(0-1)	0.5(0.12-1.5)	0.851
CD14	0.62(0.5-1)	0.75(0.25-1.5)	0.75(0.5-1.75)	1.0(0.5-1.75)	0.338
NOD1	2.0(0.25-2.75)	2.5(1-3)	2.5(1-2.75)	2.5(2-3)*§	<b>0.022</b>
NOD2	0(0-0)	0(0-0)	0(0-0)	0(0-0.25)	0.784
MYD88	1.62(0.75-2.75)	1.62(0.75-2.5)	1.5(0.75-2)	2(0.75-2.5)	0.059
TIRAP	1.5(0.75-2.75)	2(1-2.5)	1.75(0.5-2.5)	2.37(1-2.75)	0.082
Phospho-IRAK1	1.5(0.75-2)	1.75(0.75-2.5)	1.5(1-2.5)	2(1-2.25)	0.688
IRAK4	2.5(1.5-3)	2.37(1-3)	2.62(1.75-3)	2.5(1.5-3)	0.326
<b>Lamina Propria (cells/mm<sup>2</sup>)</b>					
TLR2	101(56-168)	124(45-185)	90(11-390)	150(12-470)	0.341
TLR4	62(46-129)	58(32-111)	99(40-285)&	111(27-344)&	<b>0.041</b>
TLR9	4(0-52)	5(0-15)	13(0-53)	4(0-90)	0.211
CD14	118(75-213)	133(21-376)	103(48-290)	161(60-312)	0.999
NOD1	153(37-355)	202(98-323)	229(145-419)*	286(161-475)*&	<b>0.007</b>
NOD2	0(0-9)	0(0-9)	0(0-11)	0(0-41)	0.780
MYD88	129(32-216)	128(44-275)	140(56-252)	138(44-339)	0.956
TIRAP	209(73-314)	176(101-376)	193(54-548)	258(39-548)	0.438
Phospho-IRAK1	322(232-441)	324(258-366)	344(185-419)	302(186-460)	0.550
IRAK4	155(70-406)	142(27-254)	206(64-387)	172(103-274)	0.071
CD4	164(101-212)	246(37-500)	258(107-731)	252(66-470)	0.206
CD8	147(76-301)	179(86-657)	195(86-523)	244(111-355)	0.365
CD68	284(128-516)	275(97-904)	367(158-759)	340(204-1054)	0.671
Neutrophil Elastase	93(58-166)	97(45-308)	94(28-512)	151(47-470)*&	0.045

Abbreviations: COPD, chronic obstructive pulmonary disease. Data expressed as median (range); n.d. not determined. Statistics: The Kruskal-Wallis test was used for multiple comparisons followed by Mann-Whitney U test for comparison between groups: \* $p < 0.05$ , significantly different from control non smokers; <sup>&</sup> $p < 0.05$ , significantly different from control smokers with normal lung function; <sup>§</sup> $p < 0.05$ , significantly different from mild/moderate COPD. The exact “p” values for comparison between groups are given in the Results section.

Table 3. Bacterial load in bronchial biopsies of COPD patients and control subjects

Bacterial load/mm <sup>2</sup>	Control non-smokers (n=5)	Control Smokers (n=9)	Mild/moderate COPD (n=13)	Severe/very severe COPD (n=15)	Kruskal Wallis (p value)
<b>16S</b>	5809±11269	4014±7126	6026±15477	810±1377	0.288
<b><i>Pseudomonas aeruginosa</i></b>	167±157 (78.8±23.3)	117±122 (67.2±22.6)	143±149 (77.2±23.9)	61±62 (88.8±20.2)	0.451 (0.050)
<b><i>Haemophilus influenzae</i></b>	42±59 (20.6±23.9)	51±74 (31.8±22.1)	28±38 (22.6±24.0)	5±8 <sup>&amp;§</sup> (10.7±20.5) <sup>&amp;§</sup>	0.007 (0.029)
<b><i>Moraxella catarrhalis</i></b>	0.8±1.1 (0.6±1.3)	1±2.2 (0.7±1.9)	0.1±0.3 (0.07±0.26)	0.2±0.7 (0.47±1.25)	0.567 (0.924)
<b><i>Streptococcus pneumoniae</i></b>	0.06±0.13 (0.0±0.0)	0.0±0.0 (0.0±0.0)	0.11±0.34 (0.07±0.26)	0.0±0.0 (0.0±0.0)	0.710 (0.986)

Abbreviations: 16S=total bacterial load. The bacterial load (copies/ml) is normalized for bronchial biopsy superficial layer (mm<sup>2</sup>). In brackets is the percentage of each bacterium studied over the total load value including *P. aeruginosa*+ *H. influenzae*+ *M. catarrhalis*+ *S. pneumoniae*. Data expressed as mean±Standard Error. Statistics: The Kruskal-Wallis test was used for multiple comparisons followed by Mann-Whitney U test for comparison between groups: \*p<0.05, significantly different from control non-smokers; &p<0.05, significantly different from control smokers with normal lung function; §p<0.05, significantly different from mild/moderate COPD. The exact “p” values for comparison between groups are given in the Results section.

### **Figure Legends**

**Figure 1.** Schematic representation of the molecular variations related to bacterial-related (panels a, b) molecules in the bronchial epithelium (panel a) and in the bronchial lamina propria (panel b) of control non-smokers, control smokers, mild/moderate stable COPD and severe/very severe stable COPD patients. With worsening of the disease, levels of TLR4 and NOD1 increase in bronchial epithelium (panel a) and in lamina propria (panel b). Panel (c) shows the *P. aeruginosa* and the *H. influenzae* variations in control subjects and in COPD patients of increasing severity. With worsening of the disease, levels of *P. aeruginosa* increase, while levels of *H. influenzae* decrease in bronchial biopsies. Panel (d) shows the TLR4 mRNA significant increase induced by H<sub>2</sub>O<sub>2</sub> stimulation of bronchial epithelial cells (16HBE) at 2h after the oxidative stimulus. Data in panels a, b, c, d are expressed as median±Standard Error.

\*significantly different from control non-smokers; &significantly different from control smokers; §significantly different from mild/moderate COPD. CNS=Control non-smokers; CS=Control smokers; M COPD=Mild/moderate COPD; S COPD=Severe/very severe COPD.

**Figure 2.** Regression analysis between TLR4 scored epithelial values and FEV1% predicted (panels a, c) and TLR4 scored epithelial values vs FEV1/FVC% (panels b, d). Correlations were performed in all smokers (panels a, b) and in patients with COPD alone (panels c, d). The lung functional indices of bronchial obstruction were significantly and inversely correlated to the immune expression of TLR4 in the bronchial epithelium of all smokers and of patients with COPD alone. Correlation coefficients were calculated using the Spearman rank method.

**Figure 3.** Regression analysis between FEV1% lung functional values and percentage of *P. aeruginosa* (panels a, c) and percentage of *H. influenzae* (panels b, d) in all smokers (panels a, b) and COPD patients (panels c, d). In the bronchial mucosa increased values of bronchial obstruction were associated to an increased percentage of *P. aeruginosa* in all smokers and a decreased percentage of *H. influenzae* in all smokers and patients with COPD. Correlation coefficients were calculated using the Spearman rank method.

**Figure 4.** *TLR4 and NOD1 signaling in COPD.* In the presence of concomitant oxidative stress stimuli, pathogen-associated molecular patterns (PAMPs) from micro-organisms

1  
2  
3 and endogenous molecules termed danger-associated molecular patterns (DAMPs)  
4 stimulate TLR4 leading to the recruitment of the TLR signaling adaptors myeloid  
5 differentiation primary response protein 88 (MYD88) and the adapter molecule toll-  
6 interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP). The MYD88  
7 dependent pathway recruits the IL-1R-associated kinases (IRAKs) family of proteins which  
8 leads to I $\kappa$ B phosphorylation resulting in the activation and nuclear translocation of NF- $\kappa$ B  
9 which can be responsible for the over-expression of numerous inflammatory genes. TLR4,  
10 MYD88, TIRAP and p65 (NF- $\kappa$ B) result increased in COPD patients. Bacterial PG-derived  
11 peptides  $\gamma$ -D-glutamyl-m-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP) are  
12 recognized by the cytosolic receptors termed nucleotide-binding oligomerization domain  
13 (NOD)1 and NOD2. NOD1 and NOD2 through CARD-CARD interactions may stimulate  
14 downstream IKK complex which in turn, phosphorylates the NF- $\kappa$ B inhibitor I $\kappa$ B $\alpha$  followed  
15 by the NF- $\kappa$ B activation and nuclear translocation. Gram-negative bacteria preferentially  
16 activate NOD1 which was found up-regulated in our present study in COPD patients.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Supplementary material

### Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression

Antonino Di Stefano, PhD<sup>1</sup>, Fabio LM Ricciardolo, MD, PhD<sup>2</sup>, Gaetano Caramori MD, PhD<sup>3</sup>, Ian M Adcock, PhD<sup>4</sup>, Kian Fan Chung MD<sup>4</sup>, Peter J Barnes MD<sup>4</sup>, Paola Brun, PhD<sup>5</sup>, Andrea Leonardi, MD<sup>6</sup>, Filippo Andò MD<sup>7</sup>, Davide Vallese, PhD<sup>1</sup>, Isabella Gnemmi<sup>1</sup>, Luisella Righi, MD<sup>8</sup>, Francesco Cappello, MD<sup>9,10</sup>, Bruno Balbi, MD<sup>1</sup>

#### Methods

##### *Subjects*

All COPD patients and control subjects who underwent bronchoscopy and bronchial biopsies were recruited from the Respiratory Medicine Unit of the Fondazione Salvatore Maugeri, Institute of Veruno (Veruno, Italy). In COPD patients, the severity of the airflow obstruction was graded using current GOLD criteria [<http://goldcopd.org/>]. All former smokers had stopped smoking for at least one year. COPD and chronic bronchitis were defined according to international guidelines, [<http://goldcopd.org/>]. COPD severity was graded according to international guidelines, [<http://goldcopd.org/>]. All COPD patients were stable with no previous exacerbation in the six months before bronchoscopy. None of the subjects were treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids in the month prior bronchoscopy. COPD patients were using short-acting inhaled  $\beta$ 2-agonists (SABA) or short-acting inhaled antimuscarinics (SAMA) prn or regular long-acting inhaled  $\beta$ 2-agonists (LABA) and/or regular inhaled anticholinergics, including SAMA or long-acting inhaled antimuscarinics (LAMA) at the dosage recommended in current COPD guidelines [<http://goldcopd.org/>] at the time of their recruitment. The study conformed to the Declaration of Helsinki and was approved by the ethics committees of the (formerly) Fondazione Salvatore Maugeri, (formerly),—at present: Istituti Clinici Scientifici Maugeri SpA, Società Benefit [Veruno (Novara), Italy], the University Hospital of Ferrara, Italy. Written informed consent was obtained from each subject and bronchial biopsies were performed according to the local ethic committee guidelines.

##### *Lung function tests and volumes*

1

Pulmonary function tests were performed as previously described (**E1**) according to guidelines recommendations. Pulmonary function tests included measurements of FEV<sub>1</sub> and FEV<sub>1</sub>/FVC under baseline conditions in all the subjects examined (6200 Autobox Pulmonary Function Laboratory; SensorMedics Corp., Yorba Linda, CA, USA). In order to assess the reversibility of airflow obstruction and post bronchodilator functional values, the FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% measurements in the groups of subjects with FEV<sub>1</sub>/FVC% ≤70% pre-bronchodilator was repeated 20 min after the inhalation of 0.4 mg of salbutamol.

#### *Fiberoptic bronchoscopy and bronchial biopsy processing*

Fiberoptic bronchoscopy, collection and processing of bronchial biopsies were performed as previously described (**E1**). In brief, four bronchial biopsy specimens were taken from segmental and subsegmental airways of the right lower and upper lobes using size 19 cupped forceps. Bronchial biopsies for immunohistochemistry were gently extracted from the forceps and processed for light microscopy as previously described (**E1**). At least two samples were embedded in Tissue Tek II OCT (Miles Scientific, Naperville, IL, USA), frozen within 15 min in isopentane pre-cooled in liquid nitrogen, and stored at -80°C. The best frozen sample was then oriented and 6µm thick cryostat sections were cut for immunohistochemical light microscopy analysis and processed as described below.

#### *Immunohistochemistry analysis of TLRs and NLRs signaling pathways on bronchial biopsies*

One cryostat section from each biopsy was stained with one each of a panel of primary antibodies specific for the inflammatory cells or signaling molecules studied (**Table E1**). Briefly, after blocking non-specific binding sites, primary antibody was applied at optimal dilutions and incubated for 1h at room temperature. Antibody binding was revealed with secondary anti-mouse (Vector, BA 2000), anti-rabbit (Vector, BA 1000) or anti-goat (Vector, BA 5000) antibodies followed by ABC kit AP AK5000, Vectastain and fast-red substrate (red color) or ABC kit HRP Elite, PK6100, Vectastain and diaminobenzidine (DAB) substrate (brown color). Human tonsil or nasal polyp were used as positive controls. For the negative controls, normal mouse, rabbit or goat non-specific immunoglobulins (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at the same protein concentration as the primary antibody. Double staining for identification of CD8+, macrophages (CD68+) and endothelial cells (CD31+) co-expressing TLR4 and NOD1 was also performed; briefly, mouse monoclonal antibodies used for identification of CD8+,

CD68+ and CD31+ cells were revealed using the horse anti-mouse (Vector, BA 2000) followed by ABC kit AP AK 5000, Vectastain and fast-red substrate (red color). Rabbit or goat primary antibodies for identification of NOD1 (rabbit) and TLR4 (goat) were revealed using a goat anti rabbit (Vector, BA 1000) and a rabbit anti goat (Vector, BA 5000) antibodies followed by ABC kit HRP Elite, PK 6100, Vectastain and DAB substrate (brown color). For the negative controls, normal mouse, rabbit or goat non-specific immunoglobulins (Santa Cruz Biotechnology) were used at the same combination and protein concentration as the primary specific antibodies.

#### *Scoring system for immunohistochemistry*

Morphometric measurements were performed with a light microscope (Leitz Biomed, Leica Cambridge, UK) connected to a video recorder linked to a computerized image system (Quantimet 500 Image Processing and Analysis System, Software Qwin V0200B, Leica). Light-microscopic analysis was performed at a magnification of 630x. The immunostaining for all the antigens studied was scored (range: 0 = absence of immunostaining to 3 = extensive intense immunostaining) in the intact (columnar and basal epithelial cells) bronchial epithelium, as previously described (E1). The final result was expressed as the average of all scored fields obtained from each biopsy. A mean±SD of 0.70±0.26 millimeters of epithelium was analyzed in COPD patients and control subjects. [A minimum length of 450 microns of intact epithelium was studied for each patient.](#)

Immunostained cells in bronchial submucosa (lamina propria) were quantified 100–µm beneath the epithelial basement membrane in several non-overlapping high-power fields until the whole specimen was examined. The final result, expressed as the number of positive cells per square millimeter, was calculated as the average of all the cellular counts performed in each biopsy.

#### *Quantification of the bacterial load in the bronchial biopsies*

qRT-PCR was used to quantify the 16S ribosomal subunit (total bacterial load) and the genome copy number (copies/ml) per mm<sup>2</sup> of bronchial tissue examined of *Pseudomonas aeruginosa* (*P. aeruginosa*), *Haemophilus influenzae* (*H. influenzae*), *Moraxella catarrhalis* (*M. catarrhalis*) and *Streptococcus pneumoniae* (*S. pneumoniae*). In brief, total bacterial DNA was extracted under sterile conditions from 30µm cryostat sections of bronchial biopsies using the QIAmp DNA Mini Kit (Cat. # 56304, Qiagen) following the manufacturer's instructions and re-suspended in 100µl nuclease-free water.

DNA was stored at  $-20^{\circ}\text{C}$  before amplification. DNA standards for qRT-PCR were prepared from pure DNA cultures of *Escherichia coli*, *H. influenzae*, *M. catarrhalis*, *P. aeruginosa*, and *S. pneumoniae* and were used to generate standard curves. The standard curves were always performed in triplicate with regression coefficients close to 1 (range of  $R^2$  values: 0.984-0.994 for *E. coli*, 0.986-0.999 for *H. influenzae*, 0.990-0.998 for *M. catarrhalis*, 0.987-0.999 for *P. aeruginosa* and 0.984-0.997 for *S. pneumoniae*) and showed a linear increase within the range of DNA concentration utilized.

Primers for the specific amplification of *H. influenzae*, *M. catarrhalis*, *P. aeruginosa*, and *S. pneumoniae* were synthesized by Life Technologies (Milan, Italy) and are shown in **Table E2**. DNA amplification and detection were performed in a Rotor Gene Q system (Qiagen) using the QuantiFast<sup>TM</sup> SYBER Green PCR Kit (Cat. # 204054, Qiagen). RT-PCR cycling conditions were:  $95^{\circ}\text{C}$  for 5 min (PCR initial activation step); 40 amplification cycles of  $95^{\circ}\text{C}$  for 5 s (denaturation) and  $60^{\circ}\text{C}$  for 10 s (combined annealing/extension), followed by melting curve analysis to ensure the specificity of the PCR amplification. For each reaction, negative controls were run in triplicate, consisting of primers, PCR Mastermix and sterile water instead of DNA template. Amplification, data acquisition, and cycle threshold (CT) values analysis were performed using the Rotor Gene Q software (Rotor-Gene Q Series Software 2.0.2). For each patient and control subject, an adjacent  $6\mu\text{m}$  cryostat section, stained with H&E, was used for measurement of the sub-epithelial basement membrane length. All data were expressed as number of bacterial DNA copies/ml normalized for the sub-epithelial basement membrane length multiplied by the cryostat section thickness ( $30\mu\text{m}$ ), corresponding to the square millimeters ( $\text{mm}^2$ ) of the more superficial layer of bronchial tissue examined for each subject.

#### Cell Culture and Treatments

The 16HBE human epithelial cell line was grown in Dulbecco's modified Minimum Essential Medium (DMEM), supplemented with 10% v/v fetal bovine serum (FBS), 50 IU/ml penicillin,  $50\mu\text{g/ml}$  streptomycin, 1x non-essential amino acids, 1mM sodium pyruvate and 2mM glutamine ( $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$ ). When cells were at 60-70% confluent, the medium was replaced with supplemented DMEM without FBS for starvation time (24h), followed by supplemented DMEM plus 1% FBS in the absence or presence of  $\text{H}_2\text{O}_2$  ( $100\mu\text{M}$ ) for 2, 4, 8, 16 and 24 hours. All experiments were performed at least four times (in quadruplicate).

### *Extraction and Quantification of RNA and qRT-PCR from 16HBE*

Total cellular RNA from treated and non-treated cultures was purified and isolated, using RNeasy Mini RNA Isolation kit (GE Healthcare, Buckinghamshire, UK) following the manufacturer's instructions. Total RNA was re-suspended in 100µl nuclease-free water and RNA concentration determined by spectroscopy ( $\lambda$ 260/280 nm, Eppendorf BioPhotometer plus), and stored at -80°C until use. Gene expression was measured using the Syber green for qRT-PCR in a Rotor Gene Q (Qiagen) system. One-step real-time PCR was carried out by amplifying mRNA using the QuantiFast™ SYBER Green RT-PCR Kit (Qiagen), according to the manufacturer's instructions, and gene specific primers (Qiagen) for TLR4 (Cat. # QT01670123, Qiagen) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cat # QT01192646). Cycle threshold (CT) values were determined using the Rotor Gene Q software (Rotor-Gene Q Series Software 2.0.2). The expression levels of all genes studied were normalized to GAPDH levels in each sample to determine the expression between treated and non-treated cells using the  $2^{-\Delta\Delta C_t}$  method (E2).

### *Statistical analysis*

Group data were expressed as mean (standard deviation) for functional data and median (range) or interquartile range (IQR) for morphologic data. Differences between groups were analyzed using analysis of variance (ANOVA) for functional data. The ANOVA test was followed by the unpaired t-test for comparison between groups. The Kruskal-Wallis test applied for morphologic data was followed by the Mann-Whitney U test for comparison between groups. Correlation coefficients were calculated using the Spearman rank method. Probability values of  $p < 0.05$  were considered significant. Data analysis was performed using the Stat View SE Graphics program (Abacus Concepts Inc., Berkeley, CA, USA).

6

**Table E1 Primary antibodies and immunohistochemical conditions used for identification of innate immune proteins, cytokines and inflammatory cells.**

Target	Supplier	Cat.# <sup>a</sup>	Source	Dilution	Positive control
TLR2	Serotec	AHP1424	rabbit	1:300	Nasal polyp, tonsil
TLR4	R&D	AF1478	goat	1:80	Nasal polyp, tonsil
TLR9	Serotec	AHP1823	goat	1:150	Nasal polyp, tonsil
CD14	Sigma	C7673	mouse	1:40	Nasal polyp, tonsil
NOD1	Novus Biol.	NBP131349	rabbit	1:300	Nasal polyp, tonsil
NOD2	Santa Cruz	Sc-56168	mouse	1:25	Nasal polyp, tonsil
MYD88	Santa Cruz	Sc-11356	rabbit	1:150	Nasal polyp, tonsil
TIRAP	Serotec	AHP866T	rabbit	1:300	Nasal polyp, tonsil
Phospho-IRAK1	Santa Cruz	Sc-130197	rabbit	1:50	Nasal polyp, tonsil
IRAK4	R&D	AF3919	goat	1:300	Nasal polyp, tonsil
CD4	Dako	M716	Mouse	1:100	tonsil
CD8	Dako	M7103	Mouse	1:200	tonsil
CD68	Dako	M814	Mouse	1:200	tonsil
CD31	Dako	M823	Mouse	1:40	Nasal polyp
Neutrophil elastase	Dako	M752	Mouse	1:100	Nasal polyp

<sup>a</sup>Cat#, catalogue number; (p): paraffin embedded peripheral lung tissue pretreated with citrate buffer (pH 6) and microwave exposure. See methods section for details

6

**Table E2. List of primers used for qRT-PCR of bacteria in the study of bronchial biopsies**

Primer type	Primer	Sequence (5' to 3')	Reference
16S rRNA	<i>Eub-F</i>	<i>F: 5'-TCCTACGGGAGGCAGCAGT-3'</i>	Nadkarni, 2002 <sup>a</sup>
	<i>Eub-R</i>	<i>R: 5'-GGACTACCAGGGTATCTAATCCTGTT-3'</i>	Nadkarni, 2002 <sup>a</sup>
<i>Escherichia coli</i>	<i>E.coli F</i>	<i>F: 5'-CATGCCGCGTGTATGAAGAA-3'</i>	Huijsdens, X.W., 2002 <sup>b</sup>
	<i>E.coli R</i>	<i>R: 5'-CGGGTAACGTCAATGAGCAAA-3'</i>	Huijsdens, X.W., 2002 <sup>b</sup>
<i>Haemophilus influenzae</i>	<i>HeIS-F</i>	<i>F: 5'-CCGGGTGCGGTAGAAATTAATAA-3'</i>	Rogers GB, 2014 <sup>c</sup>
	<i>Eub-R</i>	<i>R: 5'-CTGATTTTTTCAGTGCTGTCTTTGC-3'</i>	Rogers GB, 2014 <sup>c</sup>
<i>Moraxella catarrhalis</i>	<i>copB-F</i>	<i>F: 5'-GTGAGTGCCGCTTTTACAACC-3'</i>	Sethi S, 1997 <sup>d</sup>
	<i>copB-R</i>	<i>R: 5'-TGTATCGCCTGCCAAGACAA-3'</i>	Sethi S, 1997 <sup>d</sup>
<i>Pseudomonas aeruginosa</i>	<i>gyrB-F</i>	<i>F: 5'-CCTGACCATCCGTCGCCACAAC-3'</i>	Qin X, 2003 <sup>e</sup>
	<i>gyrB-R</i>	<i>R: 5'-CGCAGCAGGATGCCGACGCC-3'</i>	Qin X, 2003 <sup>e</sup>
<i>Streptococcus pneumoniae</i>	<i>Spn9802-F</i>	<i>F: 5'-AGTCGTTCCAAGGTAACAAGTCT-3'</i>	Abdeldaim GM, 2008 <sup>f</sup>
	<i>Spn9802-R</i>	<i>R: 5'-ACCAACTCGACCACCTCTTT-3'</i>	Abdeldaim GM, 2008 <sup>f</sup>


References: a) Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. *Microbiology*. 2002;148(Pt 1):257-66. b) Huijsdens XW, Linskens RK, Mak M, Meuwissen SG, Vandenbroucke-Grauls CM, Savelkoul PH. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. *J Clin Microbiol*. 2002;40(12):4423-7. c) Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, McGuckin MA, Serisier DJ. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. *Ann Am Thorac Soc*. 2014;11(4):496-503. d) Sethi S, Surface JM, Murphy TF. Antigenic heterogeneity and molecular analysis of CopB of *Moraxella* (*Branhamella*) *catarrhalis*. *Infect Immun*. 1997;65(9):3666-71. e) Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL. Use of real-time PCR with multiple targets to identify *Pseudomonas aeruginosa* and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. *J Clin Microbiol*. 2003;41(9):4312-7. f) Abdeldaim GM, Strálin K, Olcén P, Blomberg J, Herrmann B. Toward a quantitative DNA-based definition of pneumococcal pneumonia: a comparison

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

8

of *Streptococcus pneumoniae* target genes, with special reference to the Spn9802 fragment. *Diagn Microbiol Infect Dis.* 2008;60(2):143-50.

8





**E-Figure legends**

**Figure E1.** Photomicrographs showing the bronchial mucosa from control non-smokers (panel a), Control smokers with normal lung function (panel b), mild/moderate COPD (panel c) and severe/very severe COPD patients (panel d) immune-stained (arrows indicate some immunopositive cells) for identification of TLR4 in the bronchial epithelium and lamina propria. Results are representative of those from 12 non-smokers, 12 smokers with normal lung function, 16 mild/moderate COPD and 18 severe/very severe COPD patients. Negative control immunostaining, performed in a nasal polyp section, including an irrelevant goat primary antibody (not shown). Bar=30 microns.

**Figure E2.** Photomicrographs showing the bronchial mucosa from control non-smokers (panel a), Control smokers with normal lung function (panel b), mild/moderate COPD (panel c) and severe/very severe COPD patients (panel d) immune-stained (arrows indicate some immunopositive cells) for identification of NOD1 in the bronchial epithelium and lamina propria. Results are representative of those from 12 non-smokers, 12 smokers with normal lung function, 16 mild/moderate COPD and 18 severe/very severe COPD patients. Negative control immunostaining, performed in a nasal polyp section, including an irrelevant rabbit primary antibody (not shown). Bar=30 microns.

**Figure E3.** Photomicrographs showing the bronchial mucosa from severe COPD patients double-immunostained for identification of CD8+ (a, d), CD68+ (b, e) and CD31+ (c, f) cells (red-colour) co-expressing TLR4 (a, b, c, respectively) (brown-colour) and NOD1 (d, e, f, respectively) (brown-colour) in the bronchial lamina propria. TLR4 and NOD1 were revealed by diaminobenzidine substrate, whereas inflammatory cells (CD8+, CD68+) and endothelial cells (CD31+) were revealed using fast red substrate. Arrows indicate double-stained cells. Bar=15 microns.

**E-References**

E1. **Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A, Cappello F, Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B.** Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. *Thorax*. 2014;69:516-524.

E2. **Livak KJ, Schmittgen TD.** Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001;25:402-408.

## Supplementary material

### Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression

Antonino Di Stefano, PhD<sup>1</sup>, Fabio LM Ricciardolo, MD, PhD<sup>2</sup>, Gaetano Caramori MD, PhD<sup>3</sup>, Ian M Adcock, PhD<sup>4</sup>, Kian Fan Chung MD<sup>4</sup>, Peter J Barnes MD<sup>4</sup>, Paola Brun, PhD<sup>5</sup>, Andrea Leonardi, MD<sup>6</sup>, Filippo Andò MD<sup>7</sup>, Davide Vallese, PhD<sup>1</sup>, Isabella Gnemmi<sup>1</sup>, Luisella Righi, MD<sup>8</sup>, Francesco Cappello, MD<sup>9,10</sup>, Bruno Balbi, MD<sup>1</sup>

#### Methods

##### *Subjects*

All COPD patients and control subjects who underwent bronchoscopy and bronchial biopsies were recruited from the Respiratory Medicine Unit of the Fondazione Salvatore Maugeri, Institute of Veruno (Veruno, Italy). In COPD patients, the severity of the airflow obstruction was graded using current GOLD criteria [<http://goldcopd.org/>]. All former smokers had stopped smoking for at least one year. COPD and chronic bronchitis were defined according to international guidelines, [<http://goldcopd.org/>]. COPD severity was graded according to international guidelines, [<http://goldcopd.org/>]. All COPD patients were stable with no previous exacerbation in the six months before bronchoscopy. None of the subjects were treated with theophylline, antibiotics, antioxidants, mucolytics, and/or glucocorticoids in the month prior bronchoscopy. COPD patients were using short-acting inhaled  $\beta$ 2-agonists (SABA) or short-acting inhaled antimuscarinics (SAMA) prn or regular long-acting inhaled  $\beta$ 2- agonists (LABA) and/or regular inhaled anticholinergics, including SAMA or long-acting inhaled antimuscarinics (LAMA) at the dosage recommended in current COPD guidelines [<http://goldcopd.org/>] at the time of their recruitment. The study conformed to the Declaration of Helsinki and was approved by the ethics committees of the (formerly) Fondazione Salvatore Maugeri, at present: Istituti Clinici Scientifici Maugeri SpA, Società Benefit [Veruno (Novara), Italy, the University Hospital of Ferrara, Italy. Written informed consent was obtained from each subject and bronchial biopsies were performed according to the local ethic committee guidelines.

##### *Lung function tests and volumes*

1  
2  
3 Pulmonary function tests were performed as previously described (**E1**) according to  
4 guidelines recommendations. Pulmonary function tests included measurements of FEV<sub>1</sub>  
5 and FEV<sub>1</sub>/FVC under baseline conditions in all the subjects examined (6200 Autobox  
6 Pulmonary Function Laboratory; Sensormedics Corp., Yorba Linda, CA, USA). In order to  
7 assess the reversibility of airflow obstruction and post bronchodilator functional values, the  
8 FEV<sub>1</sub> and FEV<sub>1</sub>/FVC% measurements in the groups of subjects with FEV<sub>1</sub>/FVC% ≤70%  
9 pre-bronchodilator was repeated 20 min after the inhalation of 0.4 mg of salbutamol.  
10  
11  
12  
13  
14

#### 15 16 *Fiberoptic bronchoscopy and bronchial biopsy processing*

17  
18 Fiberoptic bronchoscopy, collection and processing of bronchial biopsies were performed  
19 as previously described (**E1**). In brief, four bronchial biopsy specimens were taken from  
20 segmental and subsegmental airways of the right lower and upper lobes using size 19  
21 cupped forceps. Bronchial biopsies for immunohistochemistry were gently extracted from  
22 the forceps and processed for light microscopy as previously described (**E1**). At least two  
23 samples were embedded in Tissue Tek II OCT (Miles Scientific, Naperville, IL, USA),  
24 frozen within 15 min in isopentane pre-cooled in liquid nitrogen, and stored at -80°C. The  
25 best frozen sample was then oriented and 6µm thick cryostat sections were cut for  
26 immunohistochemical light microscopy analysis and processed as described below.  
27  
28  
29  
30  
31  
32  
33

#### 34 35 *Immunohistochemistry analysis of TLRs and NLRs signaling pathways on bronchial* 36 *biopsies*

37  
38 One cryostat section from each biopsy was stained with one each of a panel of primary  
39 antibodies specific for the inflammatory cells or signaling molecules studied (**Table E1**).  
40 Briefly, after blocking non-specific binding sites, primary antibody was applied at optimal  
41 dilutions and incubated for 1h at room temperature. Antibody binding was revealed with  
42 secondary anti-mouse (Vector, BA 2000), anti-rabbit (Vector, BA 1000) or anti-goat  
43 (Vector, BA 5000) antibodies followed by ABC kit AP AK5000, Vectastain and fast-red  
44 substrate (red color) or ABC kit HRP Elite, PK6100, Vectastain and diaminobenzidine  
45 (DAB) substrate (brown color). Human tonsil or nasal polyp were used as positive controls.  
46 For the negative controls, normal mouse, rabbit or goat non-specific immunoglobulins  
47 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used at the same protein  
48 concentration as the primary antibody. Double staining for identification of CD8+,  
49 macrophages (CD68+) and endothelial cells (CD31+) co-expressing TLR4 and NOD1 was  
50 also performed; briefly, mouse monoclonal antibodies used for identification of CD8+,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 CD68+ and CD31+ cells were revealed using the horse anti-mouse (Vector, BA 2000)  
4 followed by ABC kit AP AK 5000, Vectastain and fast-red substrate (red color). Rabbit or  
5 goat primary antibodies for identification of NOD1 (rabbit) and TLR4 (goat) were revealed  
6 using a goat anti rabbit (Vector, BA 1000) and a rabbit anti goat (Vector, BA 5000)  
7 antibodies followed by ABC kit HRP Elite, PK 6100, Vectastain and DAB substrate (brown  
8 color). For the negative controls, normal mouse, rabbit or goat non-specific  
9 immunoglobulins (Santa Cruz Biotechnology) were used at the same combination and  
10 protein concentration as the primary specific antibodies.  
11  
12  
13  
14  
15  
16  
17

### 18 *Scoring system for immunohistochemistry*

19 Morphometric measurements were performed with a light microscope (Leitz Biomed, Leica  
20 Cambridge, UK) connected to a video recorder linked to a computerized image system  
21 (Quantimet 500 Image Processing and Analysis System, Software Qwin V0200B, Leica).  
22 Light-microscopic analysis was performed at a magnification of 630x. The immunostaining  
23 for all the antigens studied was scored (range: 0 = absence of immunostaining to 3 =  
24 extensive intense immunostaining) in the intact (columnar and basal epithelial cells)  
25 bronchial epithelium, as previously described (**E1**). The final result was expressed as the  
26 average of all scored fields obtained from each biopsy. A mean $\pm$ SD of 0.70 $\pm$ 0.26  
27 millimeters of epithelium was analyzed in COPD patients and control subjects. A minimum  
28 length of 450 microns of intact epithelium was studied for each patient.  
29  
30  
31  
32  
33  
34  
35

36 Immunostained cells in bronchial submucosa (lamina propria) were quantified 100 $\mu$ m  
37 beneath the epithelial basement membrane in several non-overlapping high-power fields  
38 until the whole specimen was examined. The final result, expressed as the number of  
39 positive cells per square millimeter, was calculated as the average of all the cellular counts  
40 performed in each biopsy.  
41  
42  
43  
44  
45

### 46 *Quantification of the bacterial load in the bronchial biopsies*

47 qRT-PCR was used to quantify the 16S ribosomal subunit (total bacterial load) and the  
48 genome copy number (copies/ml) per mm<sup>2</sup> of bronchial tissue examined of *Pseudomonas*  
49 *aeruginosa* (*P. aeruginosa*), *Haemophilus influenza* (*H. influenza*), *Moraxella catarrhalis*  
50 (*M. catarrhalis*) and *Streptococcus pneumonia* (*S. pneumoniae*). In brief, total bacterial  
51 DNA was extracted under sterile conditions from 30 $\mu$ m cryostat sections of bronchial  
52 biopsies using the QIAmp DNA Mini Kit (Cat. # 56304, Qiagen) following the  
53 manufacturer's instructions and re-suspended in 100 $\mu$ l nuclease-free water. DNA was  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 stored at  $-20^{\circ}\text{C}$  before amplification. DNA standards for qRT-PCR were prepared from  
4 pure DNA cultures of *Escherichia coli*, *H. influenzae*, *M. catarrhalis*, *P. aeruginosa*, and *S.*  
5 *pneumoniae* and were used to generate standard curves. The standard curves were  
6 always performed in triplicate with regression coefficients close to 1 (range of  $R^2$  values:  
7 0.984-0.994 for *E. coli*, 0.986-0.999 for *H. influenzae*, 0.990-0.998 for *M. catarrhalis*,  
8 0.987-0.999 for *P. aeruginosa* and 0.984-0.997 for *S. pneumoniae*) and showed a linear  
9 increase within the range of DNA concentration utilized.

10  
11 Primers for the specific amplification of *H. influenzae*, *M. catarrhalis*, *P. aeruginosa*, and *S.*  
12 *pneumoniae* were synthesized by Life Technologies (Milan, Italy) and are shown in **Table**  
13 **E2**. DNA amplification and detection were performed in a Rotor Gene Q system (Qiagen)  
14 using the QuantiFast™ SYBER Green PCR Kit (Cat. # 204054, Qiagen). RT-PCR  
15 cycling conditions were:  $95^{\circ}\text{C}$  for 5 min (PCR initial activation step); 40 amplification cycles  
16 of  $95^{\circ}\text{C}$  for 5 s (denaturation) and  $60^{\circ}\text{C}$  for 10 s (combined annealing/extension), followed  
17 by melting curve analysis to ensure the specificity of the PCR amplification. For each  
18 reaction, negative controls were run in triplicate, consisting of primers, PCR Mastermix and  
19 sterile water instead of DNA template. Amplification, data acquisition, and cycle threshold  
20 (CT) values analysis were performed using the Rotor Gene Q software (Rotor-Gene Q  
21 Series Software 2.0.2). For each patient and control subject, an adjacent  $6\mu\text{m}$  cryostat  
22 section, stained with H&E, was used for measurement of the sub-epithelial basement  
23 membrane length. All data were expressed as number of bacterial DNA copies/ml  
24 normalized for the sub-epithelial basement membrane length multiplied by the cryostat  
25 section thickness ( $30\mu\text{m}$ ), corresponding to the square millimeters ( $\text{mm}^2$ ) of the more  
26 superficial layer of bronchial tissue examined for each subject.

### 42 *Cell Culture and Treatments*

43  
44 The 16HBE human epithelial cell line was grown in Dulbecco's modified Minimum  
45 Essential Medium (DMEM), supplemented with 10% v/v fetal bovine serum (FBS), 50  
46 IU/ml penicillin,  $50\mu\text{g}/\text{ml}$  streptomycin, 1x non-essential amino acids, 1mM sodium  
47 pyruvate and 2mM glutamine ( $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$ ). When cells were at 60-70% confluent, the  
48 medium was replaced with supplemented DMEM without FBS for starvation time (24h),  
49 followed by supplemented DMEM plus 1% FBS in the absence or presence of  $\text{H}_2\text{O}_2$   
50 ( $100\mu\text{M}$ ) for 2, 4, 8, 16 and 24 hours. All experiments were performed at least four times  
51 (in quadruplicate).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Extraction and Quantification of RNA and qRT-PCR from 16HBE*

Total cellular RNA from treated and non-treated cultures was purified and isolated, using RNeasy Mini RNA Isolation kit (GE Healthcare, Buckinghamshire, UK) following the manufacturer's instructions. Total RNA was re-suspended in 100µl nuclease-free water and RNA concentration determined by spectroscopy ( $\lambda$ 260/280 nm, Eppendorf BioPhotometer plus), and stored at -80°C until use. Gene expression was measured using the Syber green for qRT-PCR in a Rotor Gene Q (Qiagen) system. One-step real-time PCR was carried out by amplifying mRNA using the QuantiFast™ SYBER Green RT-PCR Kit (Qiagen), according to the manufacturer's instructions, and gene specific primers (Qiagen) for TLR4 (Cat. # QT01670123, Qiagen) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cat # QT01192646). Cycle threshold (CT) values were determined using the Rotor Gene Q software (Rotor-Gene Q Series Software 2.0.2). The expression levels of all genes studied were normalized to GAPDH levels in each sample to determine the expression between treated and non-treated cells using the  $2^{-\Delta\Delta Ct}$  method (E2).

### *Statistical analysis*

Group data were expressed as mean (standard deviation) for functional data and median (range) or interquartile range (IQR) for morphologic data. Differences between groups were analyzed using analysis of variance (ANOVA) for functional data. The ANOVA test was followed by the unpaired t-test for comparison between groups. The Kruskal-Wallis test applied for morphologic data was followed by the Mann-Whitney U test for comparison between groups. Correlation coefficients were calculated using the Spearman rank method. Probability values of  $p < 0.05$  were considered significant. Data analysis was performed using the Stat View SE Graphics program (Abacus Concepts Inc., Berkeley, CA, USA).

**Table E1 Primary antibodies and immunohistochemical conditions used for identification of innate immune proteins, cytokines and inflammatory cells.**

Target	Supplier	Cat.# <sup>a</sup>	Source	Dilution	Positive control
TLR2	Serotec	AHP1424	rabbit	1:300	Nasal polyp, tonsil
TLR4	R&D	AF1478	goat	1:80	Nasal polyp, tonsil
TLR9	Serotec	AHP1823	goat	1:150	Nasal polyp, tonsil
CD14	Sigma	C7673	mouse	1:40	Nasal polyp, tonsil
NOD1	Novus Biol.	NBP131349	rabbit	1:300	Nasal polyp, tonsil
NOD2	Santa Cruz	Sc-56168	mouse	1:25	Nasal polyp, tonsil
MYD88	Santa Cruz	Sc-11356	rabbit	1:150	Nasal polyp, tonsil
TIRAP	Serotec	AHP866T	rabbit	1:300	Nasal polyp, tonsil
Phospho-IRAK1	Santa Cruz	Sc-130197	rabbit	1:50	Nasal polyp, tonsil
IRAK4	R&D	AF3919	goat	1:300	Nasal polyp, tonsil
CD4	Dako	M716	Mouse	1:100	tonsil
CD8	Dako	M7103	Mouse	1:200	tonsil
CD68	Dako	M814	Mouse	1:200	tonsil
CD31	Dako	M823	Mouse	1:40	Nasal polyp
Neutrophil elastase	Dako	M752	Mouse	1:100	Nasal polyp

<sup>a</sup>Cat#, catalogue number; (p): paraffin embedded peripheral lung tissue pretreated with citrate buffer (pH 6) and microwave exposure. See methods section for details



**Table E2. List of primers used for qRT-PCR of bacteria in the study of bronchial biopsies**

Primer type	Primer	Sequence (5' to 3')	Reference
16S rRNA	<i>Eub-F</i>	F: 5'-TCCTACGGGAGGCAGCAGT-3'	<i>Nadkarni, 2002<sup>a</sup></i>
	<i>Eub-R</i>	R: 5'-GGA CTACCAGGGTATCTAATCCTGTT-3'	<i>Nadkarni, 2002<sup>a</sup></i>
<i>Escherichia coli</i>	<i>E.coli F</i>	F: 5'-CATGCCGCGTGTATGAAGAA-3'	<i>Huijsdens, 2002<sup>b</sup></i>
	<i>E.coli R</i>	R: 5'-CGGGTAACGTCAATGAGCAAA-3'	<i>Huijsdens, 2002<sup>b</sup></i>
<i>Haemophilus influenzae</i>	<i>HeIS-F</i>	F: 5'-CCGGGTGCGGTAGAATTTAATAA-3'	<i>Rogers GB, 2014<sup>c</sup></i>
	<i>Eub-R</i>	R: 5'-CTGATTTTTTCAGTGCTGTCTTTGC-3'	<i>Rogers GB, 2014<sup>c</sup></i>
<i>Moraxella catarrhalis</i>	<i>copB-F</i>	F: 5'-GTGAGTGCCGCTTTTACAACC-3'	<i>Sethi S, 1997<sup>d</sup></i>
	<i>copB-R</i>	R: 5'-TGTATCGCCTGCCAAGACAA-3'	<i>Sethi S, 1997<sup>d</sup></i>
<i>Pseudomonas aeruginosa</i>	<i>gyrB-F</i>	F: 5'-CCTGACCATCCGTCGCCACAAC-3'	<i>Qin X, 2003<sup>e</sup></i>
	<i>gyrB-R</i>	R: 5'-CGCAGCAGGATGCCGACGCC-3'	<i>Qin X, 2003<sup>e</sup></i>
<i>Streptococcus pneumoniae</i>	<i>Spn9802-F</i>	F: 5'-AGTCGTTCCAAGGTAACAAGTCT-3'	<i>Abdeldaim, 2008<sup>f</sup></i>
	<i>Spn9802-R</i>	R: 5'-ACCAACTCGACCACCTCTTT-3'	<i>Abdeldaim, 2008<sup>f</sup></i>

References: a) Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. *Microbiology*. 2002;148(Pt 1):257-66. b) Huijsdens XW, Linskens RK, Mak M, Meuwissen SG, Vandenbroucke-Grauls CM, Savelkoul PH. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. *J Clin Microbiol*. 2002;40(12):4423-7. c) Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, McGuckin MA, Serisier DJ. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. *Ann Am Thorac Soc*. 2014;11(4):496-503. d) Sethi S, Surface JM, Murphy TF. Antigenic heterogeneity and molecular analysis of CopB of *Moraxella* (*Branhamella*) *catarrhalis*. *Infect Immun*. 1997;65(9):3666-71. e) Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL. Use of real-time PCR with multiple targets to identify *Pseudomonas aeruginosa* and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. *J Clin Microbiol*. 2003;41(9):4312-7. f) Abdeldaim GM, Strálin K, Olcén P, Blomberg J, Herrmann B. Toward a quantitative DNA-based definition of pneumococcal pneumonia: a comparison of *Streptococcus pneumoniae* target genes, with special reference to the Spn9802 fragment. *Diagn Microbiol Infect Dis*. 2008;60(2):143-50.

## E-Figure legends

**Figure E1.** Photomicrographs showing the bronchial mucosa from control non-smokers (panel a), Control smokers with normal lung function (panel b), mild/moderate COPD (panel c) and severe/very severe COPD patients (panel d) immune-stained (arrows indicate some immunopositive cells) for identification of TLR4 in the bronchial epithelium and lamina propria. Results are representative of those from 12 non-smokers, 12 smokers with normal lung function, 16 mild/moderate COPD and 18 severe/very severe COPD patients. Negative control immunostaining, performed in a nasal polyp section, including an irrelevant goat primary antibody (not shown). Bar=30 microns.

**Figure E2.** Photomicrographs showing the bronchial mucosa from control non-smokers (panel a), Control smokers with normal lung function (panel b), mild/moderate COPD (panel c) and severe/very severe COPD patients (panel d) immune-stained (arrows indicate some immunopositive cells) for identification of NOD1 in the bronchial epithelium and lamina propria. Results are representative of those from 12 non-smokers, 12 smokers with normal lung function, 16 mild/moderate COPD and 18 severe/very severe COPD patients. Negative control immunostaining, performed in a nasal polyp section, including an irrelevant rabbit primary antibody (not shown). Bar=30 microns.

**Figure E3.** Photomicrographs showing the bronchial mucosa from severe COPD patients double-immunostained for identification of CD8+ (a, d), CD68+ (b, e) and CD31+ (c, f) cells (red-colour) co-expressing TLR4 (a, b, c, respectively) (brown-colour) and NOD1 (d, e, f, respectively) (brown-colour) in the bronchial lamina propria. TLR4 and NOD1 were revealed by diaminobenzidine substrate, whereas inflammatory cells (CD8+, CD68+) and endothelial cells (CD31+) were revealed using fast red substrate. Arrows indicate double-stained cells. Bar=15 microns.

**E-References**

E1. **Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A, Cappello F, Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B.** Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. *Thorax*. 2014;69:516-524.

E2. **Livak KJ, Schmittgen TD.** Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*. 2001;25:402-408.




figure 1  
figure 1  
263x195mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




figure 2  
figure 2  
194x151mm (300 x 300 DPI)




figure 3  
figure 3  
272x206mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




figure 4  
figure 4  
158x232mm (300 x 300 DPI)




figure E1  
figure E1  
167x128mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




figure E2  
figure E2  
166x128mm (300 x 300 DPI)




figure E3  
figure E3  
107x57mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60